value innovation troper launna miehlegni regnirheob financial highlights amounts million eur unless otherwise indicated change net sales region americas europe asiaaustraliaafrica aaa business human pharma animal health biopharmaceutical contract manufacturing sales research development expenses personnel expenses average number employees operating income operating income net sales group profit group profit net sales group equity investments tangible assets depreciation tangible assets top products human pharma net sales jardiance ofev family million eur million eur summary report trajenta spiriva jentadueto million eur million eur top products animal health net sales nexgard frontline million eur million eur ingelvac heartgard circoflex flexcombo million eur million eur annual reportcontent core leitbild shareholders perspective key aspects corporate bodies group management report information group report economic position report opportunities risks report expected developments consolidated financial statements overview selected consolidated companies consolidated balance sheet consolidated profit loss statement consolidated cash flow statement statement changes group equity notes consolidated financial statements independent auditors report product portfolio human pharmaceuticals respiratory diseases cardiovascular metabolic diseases oncology diseases central nervous system infectious diseases animal health livestock swine livestock cattleruminants livestock poultry veterinary public health vph companion animals horses companion animals pets company making new better medicines humans animals heart mission create breakthrough therapies change lives independent familyowned boehringer ingelheim freedom pursue longterm vision looking ahead identify health challenges future targeting areas need good worldleading researchdriven biopharmaceutical company employees create value innovation daily three business areas human pharma animal health biopharma ceutical contract manufacturing boehringer ingelheim achieved net sales billion eur significant investment billion eur rd drives innovation enabling next generation medicines save lives improve quality life realize scientific opportunities embracing power partnership diversity experts across lifescience community working together accelerate delivery next medical breakthrough transform lives patients generations come boehringer ingelheim annual report shareholders perspective company shareholders perspective year pharmaceutical industry able demonstrate contribution society months whos declaration pandemic saw first approvals vaccines collaborative efforts across companies provided tools protect vulnerable groups importantly pharmaceutical industry also maintained supply medicines unrelated covid continued work innovative medicines despite logistical production challenges however concerning see fewer preventive screenings checkup examinations performed many patients avoided visiting medical centers boehringer ingelheim invested substantially mitigating effects pandemic patients employees partners business allowed medicines continue available patients animals despite covidrelated supply challenges time company showed significant progress pursing ambition developing breakthrough therapies humans animals successful year employees shown true agility facing challenges continue extraordinary things difficult circumstances ensure supply muchneeded medicines humans animals advancing medical progress continuously seeking solutions target areas unmet medical need people boehringer ingelheim key strengthening longterm competitiveness behalf shareholders committee would like thank everyone supported us outside boehringer ingelheim extraordinary commitment signed christian boehringer chairman shareholders committeethe board managing directors michel pairet carinne brouillonhubertus von baumbach michael schmelmer jean scheftsik de szolnok boehringer ingelheim annual report key aspects purpose transform lives driving force decades excep tion successful delivering promise last year thus improving lives many patients humans animals alike led gratifying performance organization across business areas able manage effects covid pandemic operations well pandemic shown us important pharmaceutical research medical progress societal safety see innovation key driver transform lives continued increase investments research development longterm commitment innovating unmet medical needs proving value strong pipeline promising projects stages clinical preclinical development three break therapy designations granted us us fda testament strate gy right one fourth breakthrough therapy designation followed february enabled high engagement employees support broad network partners three business units recorded profitable growth last year human pharma acceleration portfolio continued received priority review immu nology medication fast track designation treatment nonalcoholic fatty liver disease innovative medications also showed growth led jardiance ofev treatments reached seven million people worldwide company key aspects animal health good year sales competitive market like human pharma focus lies researching developing products transform lives animals strengthening capabilities increasing investments grow pipeline products livestock companion animals meanwhile continue optimize build strong base global research production marketing vienna austria inaugurated two additional facilities biopharmaceutical production network significantly increases production capacity mammalian bacteria based technology milestone investments allow us meet growing internal pipeline demand well production demand customers strongly committed bioxcellence brand last year celebrated year anniversary making health social entrepreneurs initiative well green environmental footprint program seeing impact sustainable development activities help improve environment lives humans animals decided step investment broaden commitment focused umbrella sustainable development generations bringing global sustainability initiatives together across human animal health communities environment decisive success factor personal engagement individual employee everyone contributed shared purpose transforming lives humans animals fact managed second year pandemic fills us great gratitude towards well partners signed signed signed hubertus von baumbach carinne brouillon michel pairet signed signed jean scheftsik de szolnok michael schmelmer boehringer ingelheim annual report corporate bodies shareholders committee christian boehringer chairman shareholders committee christoph boehringer erich von baumbach isabel boehringer dr mathias boehringer prof dr dr andreas barner company corporate bodies board managing directors advisory board hubertus von baumbach dr nikolaus von bomhard chairman board managing directors chairman advisory board chairman supervisory board carinne knochebrouillon mnchener rckversicherungsgesellschaft ag member board managing directors human pharma dr hagen duenbostel chief executive officer ceo kws se dr michel pairet member board managing directors dr frank mastiaux innovation chief executive officer enbw energie badenwrttemberg ag jean scheftsik de szolnok member board managing directors jan rinnert animal health chairman board managing directors ceo heraeus holding gmbh michael schmelmer member board managing directors finance group functionsdiabetes mellitus island langerhans human pancreasgroup management report information group groups business model research development production employee reporting sustainable development generations report economic position macroeconomic environment earnings position development businesses financial position net assets position report opportunities risks opportunities risk management individual risks overall statement risk situation report expected developments troper tnemeganam puorg stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report group management report information group groups business model boehringer ingelheim develops breakthrough therapies transform lives today ge nerations come independent familyowned pursue longterm vision identify tomorrows challenges seeking solutions target areas unmet medical need captured purpose transforming lives generations inspires us make significant difference human animal lives boehringer ingelheim stood innovation years among worlds leading companies sector one germanys researchfocused companies human pharma business mainstay activities accounts share overall sales business area underpinned innovative portfolio many cases products standard treatments medicine research focuses cardiovascular metabolic diseases oncology respiratory diseases immunology diseases central nervous system cns retinal health jardiance jardiance medicine treatment type diabetes also reduces risk car two new indications diovascular diseases type diabetics preexisting cardiovascular conditions heart failure groups biggest selling human pharma product third consecutive year addition us public health authority fda awarded jardiance breakthrough therapy designation btd extended use treatment heart failure moreover medicine awarded new indication eus approval use treatment heart failure reduced ejection fraction hfref first approval paraguay treatment heart failure preserved ejection fraction hfpef ofev used treatment rare respiratory disease idiopathic pulmonary fibrosis ipf increasingly also net sales business human pharma million eur animal health group million eur biopharmaceutical million eur contract manufacturing million eur sales million eur group management report information group net sales region million eur americas europe asiaaustraliaafrica aaa indication systemic sclerosis interstitial lung disease sscild registered strong growth three products also played significant role boehringer ingelheims success spiriva used treatment chronic obstructive pulmonary disease copd well asthma trajenta used treatment type diabetes pradaxa used prevent strokes patients atrial fibrillation prevention treatment thromboembolic disorders animal health business boehringer ingelheim significant provider vaccines therapeutics portfolio includes products pets horses well livestock swine ru minants poultry core brands nexgard followed frontline heartgard foundations success pets segment swine segment established swine vaccine ingelvac circoflex used treat porcine circovirus type important component companys product portfolio biopharmaceutical activities comprise manufacture human pharmaceutical products actilyse metalyse praxbind also one worlds leading providers process development commercial production biopharmaceuticals thirdparty industrial customers sales mainly comprise discontinued operations stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report financial year achieved majority sales americas europe regions asiaaustraliaafrica aaa region includes countries china strategic significance groups future development making sales research development goal research develop innovative medicines therapies treatment diseases yet satisfactory treatments available major emphasis development medicines therapies prevent detect treat chronic diseases aim make relevant contribution areas need treatment high human pharmaceuticals segment well field animal health global research network employed average people billion eur present nine countries central facilities germany biberach ingelheim rhein invested rd usa ridgefield connecticut duluth georgia st joseph missouri austria vienna japan kobe france lyon well china shanghai activities continuing expand renew existing product portfolio order safeguard groups organic longterm growth accordingly considerably increased research development rd expenses recent years past three years growth even outpaced revenue trend total around billion eur invested research development new medicines level corresponds around groups net sales research development expenses human pharma amounted billion eur research development expenses million eur net sales human pharma expenses million eur human pharma net sales animal health expenses million eur animal health net sales average number employees investments tangible assets million eur without investments infrastructure group management report information group research rely longestablished relationships academic public research institutions biotech companies pharmaceutical companies scientific field collaborating projects academic institutions spanning three continents expanding rd portfolio supplementary cooperation license agreements well acquisitions companys research activities highly productive competitive human pharma aiming source least new molecules pipeline acquisitions third parties high scientific standards business development relationships forged time early investments made boehringer ingelheim venture fund play key role success boehringer ingelheim confirmed attractiveness partner new acqui innovation network sitions partnerships human pharma business completed acquisition expanded nbetherapeutics ag start year swiss biotech company supplements research activities innovative platform development antibodydrug con jugate pipeline also completed acquisition contract manufacturer labor dr merk kollegen gmbh company subsequently renamed boehringer ingelheim therapeutics gmbh important component research activities field immunooncology strengthened activities field oncology significantly stepped past years acquisition abexxa biologics inc sep tember research collaboration established aims developing new antibodies targeting cancerspecific proteins also expanded portfolio partnerships past financial year working wellknown lieber institute brain develop ment researching new methods treating neuropsychiatric diseases also entered collaboration twist bioscience corporation headquartered san francisco collaboration objective utilize twists proprietary antibody library identify potential antibody candidates various therapeutic areas also established longterm partnerships animal health business petmedix ltd strong partner antibodybased therapies pets british company proprietary innovative platform enables rapid development antibodies longterm co operation lifebit biotech ltd provider biomedical data analyses aims utilize ai platform order rapidly identify global outbreaks infectious diseases report earlier stage pursuing basic research threeyear cooperation agreement google field quantum computing part digital transformation strategy partnership aims harness computing power new technology service boehringer ingelheims research development thus pursue innovation rapid precise manner time conserving resources stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report rd sites ah animal health hp human pharma bix bi x digital lab americas europe asia usa belgium china ames iowa ah evergem ah beijing ah athens georgia ah shanghai ah bi x germany colbert georgia ah taizhou ah biberach hp uluth georgia ah ingelheim rhein ah hp bi x japan f ulton missouri ah k atharinenhofrohrdorf ah kobe hp gainesville georgia ah ochsenhausen hp n orth brunswick new jersey ah ridgefield connecticut hp france joseph missouri ah lyon boreal ah lyon porte des alpes ah saintvulbas ah netherlands l elystad ah austria innsbruck hp vienna hp switzerland basel hp geneva hp group management report information group digital laboratory bi x focused establishing new facility shanghai well building new capabilities developing approving medical software products strategy bi x become center excellence developing medical software products throughout company well abovementioned structural development bi x organization bi x also focused solutions doctors patients human pharma business development digital products instance guard system helps general practitioners make best possible treatment decision type diabetes patients based medical guidelines since boehringer ingelheim venture fund driven innovation strategic investments young companies carrying research earlystage science technology venture fund invests biotech startup companies innovative concepts technologies potential provide groundbreaking new therapeutic platforms venture fund also founds companies identifies promising research projects uni versities academic institutions established venture fund asia alongside existing venture funds germany usa research institute molecular pathology imp vienna biomedical research insti tute wholly owned group company funded boehringer ingelheim scientists approximately countries imp conducts research molecular cellular mechanisms form basis complex biological life processes well human diseases imp one leading institutions kind late ten group leaders received least one prestigious grants awarded european research council erc success rate erc applications period imp ranked third among european research institutes universi ties six group leaders elected full members european molec ular biology organization embo open innovation platform opnmecom boehringer ingelheim contributing process scientific collaboration pharmaceutical world around molecules preclinical stage currently made available academic researchers around world freeofcharge molecules already enabled new scientific findings eg field oncology boehringer ingelheims rd activities preclinical well clinical research develop ment basis sustainable success groups positive business development past years underpinned organic process renewing portfolio based research development activities inhouse rd supplemented external cooperation partnerships also continue top priority future high commitment innovation confirmed last year means three breakthrough therapy designations granted fda may btd issued glycine transporter type inhibitor glyt bi contribution research treatment cognitive impairment induced schizophrenia month spesolimab received btd classi fication following orphan drug designation spesolimab used treating rare inflammatory disease generalized pustular psoriasis gpp addition jardiance awarded btd connection extended use treatment patients heart failure stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report human pharma new promise human pharma business rd pioneer therapies active substances transform lives patients significantly made progress focus areas cardio human pharma vascular metabolic diseases oncology respiratory diseases immunology diseases portfolio central nervous system cns retinal health human pharma portfolio included compounds whose development happened around clinical trials projects development pipeline end cardiometabolic diseases phase metabolic modulator phase angiopoietin antibody phase food intake regulator phase hemodynamic modulator phase hemodynamic modulator phase transcient receptor potential channel inhibitor phase bi glpgcgr agonist nash phase ii bi glpgcgr agonist obesity phase ii bi hemodynamic modulator ckd phase ii tenecteplase china tissue plasminogen activator ais phase iii empagliflozin new indication sglt inhibitor ckd phase iii empagliflozin new indication sglt inhibitor hf post mi phase iii empagliflozin new indication sglt inhibitor chf registration oncology phase bhcd tcell engager phase dllcd tcell engager phase cdfap antagonist phase ezabenlimab pd antibody phase exon inhibitor phase kisima cancer vaccine phase kras gc inhibitor phase lrp antagonist phase mdmp antagonist phase mek inhibitor phase ror adc phase sirp antagonist phase soskras inhibitor phase sting agonist phase trailrcdh antibody phase group management report information group development pipeline end continued respiratory diseases phase cysteine protease inhibitor phase bi antifibrotic ipf phase ii immunology phase bi kinase inhibitor cd phase ii spesolimab bi ilr antibody ppp phase ii spesolimab bi ilr antibody cd phase ii spesolimab bi ilr antibody hs phase ii spesolimab bi ilrantibody gpp registration central nervous system diseases phase phosphodiesterase inhibitor phase digital therapy phase bi trpc inhibitor mdd phase ii bi trcp inhibitor bopd phase ii bi glyt inhibitor cias phase iii stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report development pipeline end continued retinal diseases phase ischemia modulator phase neuronal damage modulator phase bi phase ii vegfang antibody wamd bi ischemia modulator dmi phase ii covid phase alteplase tpa cov iards phase iii indication abbreviations ais acute ischemic stroke cov covid induced acute mbc metastatic breast cancer atd atopic dermatitis iards respiratory distress syndrome mdd major depressive disorder bopd borderline personality disorder dmi diabetic macular ischemia mi myocardial infarction cd crohns disease gpp generalized pustular psoriasis nash nonalcoholic steatohepatitis chf congestive heart failure hf heart failure ppp palmoplantar pustulosis cias c ognitive impairment associated hs hidradentis suppurtiva tpa tissuetype plasminogen activator schizophrenia ipf idiopathis pulmonary fibrosis wamd moisture agerelated macular ckd chronic kidney disease degeneration partnered projects acquired assets study complete submissions ongoing key pipeline advances dec dec cardiometabolic diseases reported positive results emperorpreserved phase iii trial adults heart failure preserved ejection fraction without diabetes based us fda granted jardiance status breakthrough therapy reduce risk cardiovascu lar death hospitalization heart failure adults heart failure preserved ejection fraction addition announced positive results empulse trial adults hospital acute heart failure also advanced glpglucagon dual agonist already inves tigated phase ii study individuals diabetes phase ii clinical trials adults liv ing obesity nonalcoholic steatohepatitis nash addition received fast track designation us fda adults nash oncology cancer disease devastates people diagnosed also loved ones partnership wider community support awareness education improved diagnosis care patients cancer work patients throughout development process beyond ensure new treatments make meaningful difference reach patients faster need advancing unique pipeline cancer cell di rected agents immunooncology therapies combination approaches help win fight cancer group management report information group respiratory diseases research development new therapeutic options people respiratory diseases another focus boehringer ingelheim since ofev nintedanib treatment option idiopathic pulmonary fibrosis ipf slow decline lung function breakthrough pulmonary fibrosis therapy achieved leading two new indications systemic sclerosisassociated interstitial lung disease sscild chronic fibrosing interstitial lung diseases progressive phenotype pfild building foundation ap provals countries ofev approved treatment ipf countries countries sscild countries pfild almost countries first approved treatment option sscild und pfild ongoing openlabel extension trials senscison inbuildon provide data longtime safety efficacy nintedanib sscild pfild additionally inpedild study investigating dosing safety profile nintedanib children adolescents despite advances therapy still high unmet therapeutic need fibrosing pulmonary diseases therefore investigating safety tolerability bi patients ipf clinical trial making good progress immunology immunological diseases greatly impact lives people living emotionally physi cally boehringer ingelheim dedicated discovering developing firstoftheirkind thera pies serious inflammatory diseases deep understanding molecular pathways pioneering scientific breakthroughs target repair prevent inflammatory diseases skin gut joints spesolimab advanced investigational compound boehringer ingelheims immunology pipeline filed marketing authorization fda ema chinese japanese authorities treating patients flare generalized pustular psoriasis filing based positive phase ii data effisayil trial addition spesolimab granted breakthrough therapy designation china usa central nervous system boehringer ingelheim redefining mental health enable people thrive decade ago boehringer ingelheim embarked research domain criteria rdoc inspired approach link behavior underlying neurobiology develop targeted therapies ease burden conditions symptoms one example approach bi currently investigate clinical phase ii trials people living borderline personality major depressive disorder boehringer ingelheim initiat ed innovative connex phase iii clinical trial treatment cognitive impairment associated schizophrenia cias based successful phase ii trial cias us fda granted breakthrough therapy designation bi novel glycine transport er glyt inhibitor indication stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report retinal diseases retinal diseases agerelated macular degeneration leading cause legal blind ness developed world although current therapies retinal diseases exist limited effectiveness real world significant unmet treatment needs still exist boehringer ingelheim continued developing advancing retinal health pipeline clinical development several new compounds started potential treat wet agerelated macular degeneration geographic atrophy boehringer ingelheim also transi tioned potential treatment diabetic macular ischemia dmi phase ii trial work scientists complemented collaborations academic patient organizations alongside partnerships biotech companies covid researchdriven biopharmaceutical company utilize different areas expertise find medical treatments covid initiated three programs develop new therapy options thus fully concentrating efforts area development alteplase potential treatment covid patients severe breathing problems called acute respiratory distress syndrome ards currently compound investigated phase iii part tristards phase iiiii study two programs discon tinued development bi patients hospitalized covid respiratory complications due lack efficacy bi sarscov neutralizing antibody due lack coverage delta variant group management report information group following table shows relevant changes current clinical studies phase iii clinical trial phase changes emperorpreserved nct phase iii phase iii study completed primary endpoint met randomized doubleblind trial investigating published new england journal medicine daily empagliflozin compared placebo empagliflozin demonstrated percent adults chronic heart failure preserved duction combined risk cardiovascular ejection fraction without diabetes death hospitalization heart failure receiving current standard care adults heart failure preserved ejection fraction empagliflozin also reduced first recurrent hospitalizations heart failure percent significantly slowed kidney function decline empulse nct multicenter ran phase iii study completed primary endpoint met domized doubleblind day superiority trial empulse phase iii study empagliflozin shows evaluate effect clinical benefit safety significant clinical benefit adults stabilized tolerability daily oral empagliflozin mg acute heart failure hospital adults compared placebo initiated patients hospital hospitalized acute heart failure per ized acute heart failure de novo decompen cent likely experience clinical benefit sated chronic hf stabilized treated empagliflozin pla cebo benefit consistent people new existing heart failure regardless ejection fraction diabetes status effisayil nct week phase ii study completed primary endpoint met phase ii trial investigating patients gpp published new england journal medicine flare n patient randomized data showed spesolimab novel il treated intravenously either mg antibody treatment effective rapidly spesolimab placebo primary endpoint treating adult patients generalized gpp physician global assessment gppga pus pustular psoriasis gpp experiencing flare tulation subscore visible pustules week one key secondary endpoint gppga score clearalmost clear skin week one connex phase iii clinical trial program phase iii start phase iii designed assess safety efficacy bi improving cognition adults schizophrenia program comprised three clinical trials phase iii randomized doubleblind placebocontrolled parallel group trials examine efficacy safety bi daily week treatment period patients schizophrenia tristards nct seamless phase iii start phase iii openlabel randomized parallelgroup phase iib iii trial evaluates efficacy safety daily intravenous alteplase five days top best available medical management stand ard care compared best available medical management alone adults covid acute respiratory distress syndrome ards primary objective trial time clinical improve ment hospital discharge stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report animal health area animal health boehringer ingelheim concentrates discovery devel opment treatments preventive therapies areas medical need unmet efforts greatest impact targeted therapeutics oncology immunology new chemical entities new methods control counter resistance par asites well new tools technologies improve prevention infectious diseases current portfolio includes innovative vaccines antiparasitics protection live stock pets well pharmaceutical products treatment chronic diseases research increasingly incorporates new approaches technologies use stem cells monoclonal antibodies innovation strategy built scientific approach investigation causes mechanisms diseases across multiple species including animals humans leading discovery new ways mitigate causes intervene disease process broad approach enables us work close cooperation human pharma colleagues well external partners areas outside animal health three strategic areas infectious disease noninfectious disease parasiticides use strategy target solutions broadly applied across species infectious disease eg vaccines focus areas innovation mucosal immunity bacterial disease transboundary emerging diseases noninfectious disease eg therapeutics focus collaboration human pharma grow capabilities key technologies targeted external partnerships parasiticides focus maintaining leadership acceleration key discovery development programs new molecules investment innovative technologies long term including solutions address sustainability research development sites organized six regional innovation centers located usa europe china organization supports global innovation strategy en suring concentration critical mass expertise needed deliver therapies customers key geographies specific sites within region serve focus competencies particular segments overall strategy footprint strengthens local execution facil itates regional external networks partnerships synergies key strategic advantage boehringer ingelheim retain human pharma collaboration animal health divisions exploiting synergies already suc human pharma cessfully introduced products vetmedin semintra metacam aservo animal health equihaler additional promising compounds pipeline expect innova tion connection particularly area therapeutics external partnerships also play key role demonstrated integration global stem cell technology nv later renamed boehringer ingelheim veterinary medicine belgium company specialized stem cell therapies orthopedic immunological animal diseases already acquired cooperation led first stem cellbased animal health product articell forte approved european commission initiated number new strategic partnerships including partnership petmedix whose platform generates canine therapeutic antibodies use developing therapies immunemediated conditions cancer allergy arthritis also partnering lifebit aid detecting early reporting global infectious disease outbreaks ai platform furthermore continue work key research institutions friedrichloeffler institut pirbright institute oxford university innovation develop effective ap proaches prevent african swine fever threatens swine industry worldwide group management report information group initiated research development clinical studies worldwide awarded product authorizations new regulatory approvals clude nexgard combo eu canada extends one flagship parasiticide brands cats nexgard spectra brazil new market broad spectrum product treats endo ectoparasites usa received approval flex parvoprrs combination vaccine effective reproductive failure caused two common viral causes porcine reproductive failure globally obtaining approvals new products new areas application expanding geographic scope sales activ ities existing products additional important aspects research development activities help us create value innovation production human pharma human pharma business globally active production facilities responsible steady supply topquality medicines patients ongoing development companys internal production facilities strategic cooperation external manufacturers es tablished modern flexible market supply network encompasses entire value chain suppliers starting materials worldwide logistics distribution finished phar maceutical products boehringer ingelheims production facilities concentrate products strategically important company well stateoftheart manufacturing tech nologies time partnerships external manufacturers add specialist technolo gies production network available inhouse also expand production capacity standard technologies products high capacity requirements already far advanced terms life cycle financial year global network included boehringer ingelheims plants nine countries group four biopharmaceuticals facilities also two facilities manufacture pharmaceutical active substances one produces medical devices finished pharmaceutical products manufactured eight facilities past year characterized unusual logistical challenges due covid pandemic boehringer ingelheim able ensure steady supply medicines patients possible thanks establishment key manufacturing steps technologies multiple facilities strengthening resilience concept every link supply chain progressing digitalization production network overall supply chain played key role ongoing development measures ensure security supply ongoing im plementation groups supply chain strategy optimizes value chain management supplier customer endtoend use digital automated processes technologies enables high level transparency efficient management global pro duction network supply chain delivery capacity patient care top priorities boehringer ingelheim company con sistently makes important investments development transformation production capacities chemical pharmaceutical network ingelheim rhein headquar ters made key investment flexible plant industrialization newly developed medicines initial market supply made progress expansion production technologies capacities pharmaceutical active substances fornovo italy facility pharmaceutical bulk drugs sant cugat spain facility finished pharmaceutical products koropi greece yamagata japan facilities ensure supply anti diabetic products jardiance particular well pipeline products opening stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report production facilities ah animal health hp human pharma bio biopharmaceutical contract manufacturing americas europe asiaoceania brazil belgium great britain china itapecerica hp evergem ah pirbright ah nanchang ah paulnia ah shanghai hp bio denmark italy taizhou ah mexico kalundborg ah fornovo hp g uadalajara ah noventa ah indonesia germany xochimilco hp bogor hp biberach bio austria puerto rico dortmund hp vienna bio japan barceloneta ah ingelheim rhein hp yamagata hp spain usa france sant cugat hp new zealand athens georgia ah lyon ah auckland ah fremont california bio toulouse ah gainesville georgia ah st joseph missouri ah greece koropi hp grand lyon industrial biologic center lpa st priest lentilly jonage group management report information group biopharmaceutical largescale cell culture production building vienna facility represented milestone expansion capacities network newly developed products together production facilities global biopharmaceutical network covers among activities increased demand actilyse metalyse animal health animal health products manufactured network production facilities eleven countries addition companys facilities around contract man ufacturers turned medicines boehringer ingelheim companys product comprises vaccines pharmaceutical products nutraceuticals traditional medicines supple animal health mented diagnostic products well monitoring solutions including digital applications production facilities used livestock monitoring link livestock owners veterinarians opti eleven countries mization companys production network continues remains priority goal ensuring reliable efficient supply products boehringer ingelheim invested capacity expansion strongest revenue con tributor nexgard barceloneta puerto rico facility expansion small animal vaccine production companys facility athens georgia usa expansion vaccine capacity lyon france st joseph missouri usa capacity expansion footandmouth disease vaccines jonage france well expansion pharma ceutical manufacturing capacities toulouse france also invested development modern technologies manufacture products biopharmaceutical contract manufacturing boehringer ingelheim pursues biopharmaceutical activities facilities biberach one leading germany vienna austria fremont california usa shanghai china comprise biopharma provid manufacture ownbrand marketable products actilyse metalyse ers industrial praxbind manufacture biopharmaceuticals clinical testing pipeline products customers one worlds leading companies process development launch preparation com mercial production biopharmaceuticals thirdparty industrial customers twelve top pharmaceutical companies innovative biotech firms clients biopharmaceutical contract manufacturing business boehringer ingelheim covers entire biopharmaceutical value chain development production cell mammalian cells well microorganisms production process manufacture active substance finished pharmaceu tical product product launch global market supply stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report capacity utilization established networks industrialscale production facilities remained high level biberach facility optimized production process suc cessfully demonstrated bioequivalence study along rampedup production meet growing market demand actilyse achieve rapid increase production volumes initiated transfer optimized process new largescale cell culture plant vienna way support process submission authorities eu usa japan biberach launched preparatory activities boehringer ingelheims ilr monoclonal antibody spesolimab expected introduced market microbial production facility vienna site approved customer product carrier protein vac cines microbial product portfolio thus increased biopharmaceuticals despite challenging external conditions associated covid pandemic cell culture plants biberach shanghai fremont microbial production vienna continued man ufacture deliver biopharmaceuticals patients worldwide without incurring interruptions expansion cell technology capacity vienna facility completed past year local authority authorized commissioning compliance good manufacturing practices gmp halfway year transfer production activities currently un derway also vienna facility completed microbial expansion project production recombinant vaccine view growing global importance biotechnologically produced active substances significant increase number internal development projects portfolio two projects key strategic relevance shanghai facility focused market supply immunooncological antibody chinese customers cancer therapy also expanded customer product portfolio facility shanghai china filed facilitys approval us mar ket activities focus supply innovative medicines patients chinese multinational biopharmaceutical companies customers greatly benefit fact boehringer ingelheim contract development manufacturing organization able cover entire value chain single source longterm experience technical expertise preparation product launches market supply employee reporting boehringer ingelheim employed people average worldwide represents increase previous year average number employees region americas europe asiaaustraliaafrica aaa group management report information group committed employees identify companys aims appreciate respectful work climate boehringer ingelheim major success factor driving groups positive growth high level personal commitment help us fulfill joint promise ensuring supply vital medicines holds particularly true worldwide pan demic annual global employee survey provides us relevant feedback enables us continuously improve work environment boehringer ingelheims success based innovation well presence countries global nature value chain international nature clientele stringent greatly varying requirements national regulators demand great flexibility organiza tion whole convinced relationships based trust well mutual openness respect empathy values make us strong competitive diversity thought spirit inclusion relationships one another promote capacity innovation every area business addition competitive salaries boehringer ingelheim offers benefits employ ees benefits include range company pension plans flexible homebased work options numerous healthrelated benefits human resources department respon sible promoting wide range opportunities innovation work signifi cant aspect corporate strategy helping employees nurture personal strengths developing individuals order best prepared challenges ahead emphasize acquisition technical expertise part comprehensive qualification system vocational training always major importance boehringer ingelheim company provides young people career entry opportunities time also retain talented wellqualified workforce young professionals times demographic change however company vocational training mean passing expertise emphasize getting know one another enable young professionals experience many aspects company values achieve goal means hybrid learning teaching average young people worldwide enrolled boehringer ingelheims vocational training program boehringer ingelheims german facilities alone young people started careers different scientific technical commercial fields training dualstudy courses selection training dualstudy courses closely coordinated disciplines ensure curricula training programs meet needs one companys important aims strengthen appeal boehringer ingelheim boehringer employer current future employees boehringer ingelheim ingelheim recognition top employer auditors international independent top recognized employers institute awards countries three regions represent increase global top nine awards compared previous year also mean boehringer ingelheim employer first time global top employer approximately companies received awards awarded distinction worldwide addition germany boehringer ingelheim also granted distinction argentina australia austria brazil chile china colombia ecuador hungary indonesia italy malaysia mexico netherlands new zealand philippines poland romania russia saudi arabia singapore south korea spain thailand united kingdom vietnam stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report sustainable development generations sustainable sustainability firmly anchored corporate philosophy since boehringer ingelheims development founding understanding awareness sustainability continuously devel part strategy oped generations influences decisionmaking actions also learned global pandemic made obvious imperative holistic approach address intertwined connection humans animals environment focus human animal health boehringer ingelheim well positioned provide relevant contribution healthier sustainable future updated sus tainability strategy entitled sustainable development generations process focus following definition designated impact areas stronger usage syn ergies unifying companys global collaborative network well ensuring alignment un sustainable development goals strategy based following three pillars health people animals potential communities people green planet boehringer ingelheim aims achieve following concrete measurable goals health expanding access healthcare additional million people vulnerable communities investing billion eur health innovation research tackle non communicable diseases additional million eur partnerships combat emerg ing infectious diseases potential aim positively impact million people vulnerable communities empowering supporting employees partners innovative social entrepreneurs green become carbonneutral company operations scope also significantly reduce resource footprint across value chain period despite growing business activities group management report information group health people animals health follows ambition develop better therapies enable better solutions health global healthcare challenges pillar includes number projects initiatives reflecting focus diversity patients expertise partners include health people animals access healthcare access healthcare initiative seeks improve healthcare vulnerable communi ties starting availability medicines access safe effective prevention care achieved several milestones example expanding access healthcare less developed regions un defeatncd partnership launched joint initiative pharmaccess part reach africa program kenya mobile technology improves awareness hypertension diabetes lowers barriers access pathway project fund launched canada intends improve lives members indigenous communities project address exces sive prevalence certain noncommunicable diseases communities pilot program launched pakistan collaboration world organi zation animal health supports elimination rabies donating animal vaccine rabisin dog identification collars angels angels initiative established improve stroke care worldwide ad ditionally around clinics countries doctors nurses joined contin uously growing network includes healthcare professionals clinics countries helps ensure patients treated line defined standards ngels initiative featured access medicine report best practice example capacity building distinguished world stroke organizations stroke service award lastmile south sahara smallholder farmers africa often lack access veterinary treatment joint initiative lastmile aims achieve longterm sustained improvement availability veterinary products services project launched kenya since expanded cameroon nigeria mali burkina faso ethiopia currently lastmile live stock service providers llsps working field relevant veterinary medicine farm management modules added llsp training programs four new prod ucts included product portfolio subsequently total products included total lastmile assisted many farmers provided numerous animal trader visits veterinarian visits stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report potential communities people potential potential focused providing safe also best possible conditions focus people order people boehringer ingelheim communities partners reach communities full potential safe safe program established place particular emphasis ensuring safe workplaces employees partners therefore continuously reviewing optimizing work safety culture strive maintain employees longterm good health preventing accidents incidents occupational health risks boehringer ingelheim became official partner euosha healthy workplaces lighten load campaign prevent workrelated musculoskeletal disorders msds addition spring internal campaign shed light launched raise awareness mental health issues workplace encourage employees speak address diversity inclusion core values empathy respect passion trust foster diverse collabo rative open inclusive work environment key innovation value creation sustainable growth boehringer ingelheim convinced valuing diversity right thing people communities also smart thing business since helps us understand fulfill different needs requirements patients customers partners around globe continued focus awareness education included updating training programs topics unconscious bias inclusive behavior human rights boehringer ingelheim continuously stepping efforts areas human rights ethics approach aligned united nations guiding principles business human rights subsequently human rights policy integral component guide lines cooperation external partners eg code conduct making health boehringer ingelheim ashoka worlds largest network social entrepreneurs jointly established making health mmh initiative longterm partnership fo cuses enabling innovative solutions tackle complex healthcare challenges people animals communities approach links interdependent issues economic development infrastructure education culture healthcare issues emphasizes collabora tion communities equal partners engages boehringer ingelheim employees share knowledge skills highlights include social innovation date innovators worldwide working areas human animal health supported community activation since programs initiated india kenya nigeria ghana already impacted lives proven game changers includes clean water hygiene projects implementing innovative farming models providing animal health business skills training courses well inclusion programs marginalized community groups people albinism group management report information group crosssector collaboration making health emphasizes winwin collaborative approach bridge gap business society one initiative busi ness accelerator funding program initiative provides funding expertise support social startups subsaharan africa enabling scale sustain business models many social enterprises progressed stage sub stantial funding necessary subsequently new initiative boehringer ingelheim social engagement launched investment million eur offer addition corporate donations alterna tive financing opportunities social entrepreneurs includes example provision subordinate loans whose terms conditions would adjusted local needs requirements social enterprises also mmh connect platform launched aims enable match boehringer ingelheim employees support effective innovative partnerships social enterprises able contribute skills also develop ing individuals making health together convention twoday virtual event brought together participants across academia nonprofit industry political sectors interactive sessions participants discussed resolve worlds pressing healthrelated issues green planet healthy planet prerequisite healthy people animals communities environmental green challenges seen isolation tangible effects health whole focus societies sustainable use natural resources promotion strong environmental environment awareness subsequently key components environmental sustainability program order help protect health current future generations safeguard prospects healthy future green fund supports internal projects areas decarbonization water management circular economy already provided funding approximately new environmental projects worldwide since boehringer ingelheim pays particular attention ecological aspects major projects set aside additional mil lion eur purpose boehringer ingelheim first pharmaceutical company eu receive greencanteen certification sustainable catering concept ingelheim headquarters stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report carbon footprint continuously working reducing greenhouse gas emissions committed becoming carbonneutral operations scope using renewable electricity continuing make substantial investments sustainable technology one tools used process introduction internal carbon price eur per ton create additional economic incentive green innovation recent examples activities include construction new biomass power plant ingelheim transition renewable electricity solutions numerous locations including sites germany austria spain usa since companys share renewable elec tricity purchased worldwide increased certification carbon neutrality sites dortmund sant cugat partnership climateseed supports biodiversity protects drinking water offsetting carbon emissions among others reforestation projects africa india indonesia germany resource use circular economy aspects implemented stages value chain minimize waste apply ecodesign green chemistry concepts new products continuous opti mization measures reduced annual volume waste landfills resource use since thus optimizing environmental footprint future boehringer ingelheim products water stewardship access clean water major impact social cultural justice environmental sus tainability local economy reason boehringer ingelheim implements programs related water related risks production sites sites established water scarcity areas implement recognized water stewardship program alliance water stewardship aws aws certification promeco production facility xochimilco mexico renewed aws certification process production facility fremont california usa initiated furthermore evaluated wastewater production sites regarding possible residues active pharmaceutical ingredients api trace substances basis clean water initiative ensures traces pharmaceuticals wastewater remain signifi cantly effect level initiative also works industrial networks suppliers cover entire value chain context boehringer ingelheim finances joint projects making health kenya aim improve access clean water group management report report economic position report economic position macroeconomic environment world economic output recovered following covidrelated collapse according international monetary fund imf global economy grew first six months year many economies experienced upswing due easing measures introduced order contain pandemic account increased level consumer demand growth slowed second half year due factors including industrial enterprises continuing global supply capacity bottlenecks well rising commodity prices freight costs trade policy situation usa china remained tense increase tensions reflect ed factors increased import duties also conflict russia ukraine closely monitored also signs rising inflation unlike sectors pharmaceutical markets tend shaped longterm economic output growing human particular societies demographic trends performance also influenced pharma market continuous global improvement access healthcare global pharmaceutical market allowed increased including covid vaccines thus increased trillion usd past year corre investment rd sponds average annual rate growth past five years source iqvia ever developing countries growth contribution decreased relative situation start decade pharmaceutical industry social distancing measures resulted delays clinical studies thus impacted schedules research activities compensat ed additional costs possible largely stable core business comparison industries allowed pharmaceutical companies remain key driver investment research development including fight sarscov virus healthcare systems around globe pressured covid pandem ic burden chronic diseases aging populations increased budget pressure order address challenges governments healthcare authorities expanding use costcontainment actions including mandatory price reductions external reference pricing lengthy well complex negotiation processes delays access innovative new med icines also patient increasingly involved cost treatments different forms copayments measures increasingly putting pressure pharmaceutical com panies thus might limit future ability invest development new treatment options improve access innovative medicines pharmaceutical industry working together governments healthcare authorities address challenges thus maintain improve sustainable patient access reduce access delays continuously bring innovation patients important prerequisite achieving objective remains reliable legal framework promotes innovation ensures protection intellectual property animal health market consisting pet livestock segments continued pos animal health itive growth trend mainly reflects population growth many peoples rising living market continues standards emerging markets animals improved life expectancy due continuous positive growth advances veterinary care pet segment pets growing popularity due covid trend pandemic prompted increased level demand products livestock segment bene fiting growing demand animal products increasing prevalence zoonoses infec tious diseases transmissible animals humans humans animals stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report reinforcing importance animal health industry general consolidation mergers supplier customer sides ongoing resulting increased com petition future growth animal health business largely driven therapeutic innovation order grow market investments need continuous sustainable competitive according imf global economy grow advanced economies broad access covid vaccines expected made pandem icrelated decline economic output end moreover many different scenarios regard inflation trend inflation might return prepandemic level however according imf also large number risks associated world economic growth vaccineresistant mutations covid pathogen uneven access vaccines resulting increasing gaps developing countries emerging markets advanced economies addition ongoing climate change increasing risk natural disasters thus related health economic impacts currency trends boehringer ingelheims global presence means currency trends influence revenue fig ures us dollar usd japanese yen jpy chinese renminbi cny particu larly worthy note following low eurusd january start year us dollar reached high eurusd december end year japanese yen fluctuated high eurjpy january low eurjpy june start year chinese renminbi low eurcny january reached high eurcny end year december significant transactional currency risks hedged suitable currency instruments currency development effect net sales average rate basis eur million eur us dollar japanese yen chinese renminbi earnings position stable competitive earnings position solid financing guarantee boehringer ingelheims independence therefore central activities basis pursue guiding principle value innovation contribute improvements human animal health means innovative therapies group management report report economic position boehringer ingelheims positive growth trend remained intact recorded net sales million eur represents increase relative previous years net sales figure million eur exchange rate effects adversely affected sales trend adjusted effects group achieved growth rate billion eur net sales achieved sales growth every region previous years sales million eur growth share overall sales americas region boehringer ingelheims key sales regions market grew currencyadjusted europe region registered strong est level sales growth past financial year rate currencyadjusted sales volume amounted million eur represents share group sales positive trend mainly driven global licensing business allocated region well markets germany spain united kingdom countries eastern europe asiaaustraliaafrica aaa region sales increased currencyadjusted million eur especially due institutional price adjustments core market degree continuing effects covid pandemic course business aaa region unable emulate growth rates registered previous years net sales region million eur currency change adjusted americas europe asiaaustraliaafrica aaa human pharma business made products available pa tients thanks new approvals additional countries also strengthened established products include products jardiance family ofev especially global licensing business also provided significant growth contribution rd pipeline devel oping positively important milestones reached animal health business grew particularly pet segment biopharmaceutical contract manufacturing business commissioning largescale cell culture plant vienna key milestone us highlight financial year key figures million eur change net sales operating income return net sales income taxes income taxes stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report materials ratio taking consideration change inventory rose slightly personnel expenses increased primarily due additional employees hired areas research development medicine biopharmaceutical med icine production strategic significance boehringer ingelheim amortization intangible assets depreciation tangible assets mil lion eur lower compared previous year particularly attributable high vol ume impairment losses intangible assets financial year hand continuing high level investment activity acquisitions resulted increased amortization intangible assets depreciation tangible assets achieved growth businesses financial year operating come increased million eur positive sales trend businesses enables us make longterm investments research development increased research development expenditure percentage net sales financial year return sales fell due higher prices procurement markets increased number employees strategically important areas invest ments financial income holding income influenced oneoff effects previous years holding income included profit sale investment thus lower reason especially financial income improved particular due new method introduced measurement longterm obligations income taxes therefore rose particularly due higher operating income income taxes likewise higher previous year reflected improved pretax profit well lower income taxes must noted regard pro visions german commercial law shareholders personal taxes arising group business activities may recognized tax expenses instead taxes presented part withdrawals group equity taking specificity account actual tax ratio markedly higher figure shown profit loss statement despite challenging market conditions business areas heightened cost pres sure boehringer ingelheim registered positive performance financial year fol billion eur lowing group profit million eur previous year figure rose group profit million eur million eur group management report report economic position development businesses past year boehringer ingelheims activities divided human pharma animal health biopharmaceutical contract manufacturing businesses net sales business million eur currency change adjusted human pharma animal health biopharmaceutical contract manufacturing sales discontinued operations human pharma human pharma business mainstay boehringer ingelheims activities accounts share groups net sales sales human pharma business increased currencyadjusted financial year million eur growth mainly driven established products jardiance family well ofev growing volume licensing business particular skyrizi licensed abbvie responsible marketing product also made key contribution positive development human pharma business human pharma net sales top products million eur currency change adjusted jardiance family ofev trajenta jentadueto spiriva pradaxa strongest revenue contributor jardiance used treat type jardiance diabetes jardiance family generated net sales million eur thus ofev drive growth currencyadjusted higher previous year ofev boehringer ingelheims second biggestselling product mainly used treat idiopathic pulmonary fibrosis two additional indications sscild pfild ofev recorded net sales million eur thus achieved growth rate currency adjusted unlike previous year trajenta jentadueto used treat type diabetes returned sales growth sales increased currencyadjusted million eur stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report spiriva used treatment chronic obstructive pulmonary disease copd registered declining sales figures reflects stage product reached life cycle line expectations net sales volume million eur currencyadjusted lower previous year sales anticoagulant pradaxa fell currencyadjusted yearover year however sales volume million eur pradaxa remained one boehringer ingelheims five biggestselling medicines financial year sales growth currencyadjusted likewise registered licensing income provided skyrizi product marketed globally partner abbvie based risankizumab medication treatment plaque psoriasis mainly devel oped boehringer ingelheim medicine also approved several markets treatment crohns disease psoriasis arthritis sales volume financial year thus also reflects related oneoff milestone payments human pharma business achieved growth every region yearoveryear terms regional distribution revenue usa remained strongest revenue contributor growth rate currencyadjusted million eur represents almost share human pharma businesss overall sales volume achieved net sales million eur eucan region europe canada australia new zealand growth rate currencyadjusted eucan region thus gained importance share sales points higher previous year companys emerging markets also registered improved volume sales past finan cial year growth rate currencyadjusted overall sales coun tries rose million eur however singledigit growth emerging markets fell short expectations chinese market particularly challenging sales fell currencyadjusted due inclusion core products countrys national reim bursement drug list use volumebased procurement mechanisms japan accounted almost total net sales human pharma business sales rose currencyadjusted million eur human pharma net sales region million eur currency change adjusted usa eucan emerging markets japan animal health past financial year animal health business achieved net sales totaling mil lion eur thus provided almost groups sales animal health increased sales volume currencyadjusted thus stepped pace growth relative previous year growth driven pet segment group management report report economic position animal health net sales top products million eur currency change adjusted nexgard frontline heartgard ingelvac circoflex flexcombo segment accounts biggestselling medicines animal health business pet segment tiparasitics nexgard frontline registered growth rates currencyadjusted drives growth currencyadjusted past year nexgard achieved sales volume million eur thus remained biggestselling product animal health portfolio frontline secondbiggest seller revenue million eur medicine heartgard suffered decline currencyadjusted sales past financial year product used prevent heartworm disease contributed mil lion eur animal health business sales volume swine vaccine ingelvac circoflex also registered declining sales volume revenue fell currencyadjusted million eur least due continuing challenges associated african swine fever key markets animal health business surpassed previous years sales volume every region usa achieved currencyadjusted growth registered positive course business financial year particularly pet segment including horses compensated slightly lower sales figure swine segment eucan region likewise registered strong sales growth pet segment hand growth swine poultry segments failed match expectations overall sales growth eucan region amounted currencyadjusted tcm region chinese market improved sales volume currencyadjusted yearoveryear growth mainly driven swine segment alamea asia latin america middle east africa region registered sales growth currencyadjusted sales pet segment higher livestock segment animal health net sales region million eur currency change adjusted usa eucan alamea tcm stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report biopharmaceutical contract manufacturing continued strong biopharmaceutical contract manufacturing business revenue currency growth adjusted higher previous year due strong demand business biopharmaceutical partners market products order situation entire business developed positively contract resulting high level capacity utilization manufacturing salesdiscontinued operations discontinued operations aggregate activities minor strategic importance boehringer ingelheim net sales decreased expected financial position boehringer ingelheims financial management strategy aims safeguard companys financ ing means operating cash flow far possible minimize financial risks optimize cost capital cash inflow operating activities amounted million eur attributable positive business performance financial year million eur lower previous year million eur mainly due increase receivables higher tax payments million eur financial funds cash flow operating activities cash flow investing activities cash flow financing activities change financial funds cash relevant transactions change financial funds due exchange rate movements valuation adjustments financial funds cash outflow investment activities increased significantly million eur million eur financial year cash holdings funds previously invested current assets invested longterm securities addition previous year included oneoff payments share business divestitures high capital milestones achieved context large investments tangible assets expenditure volume expansion production facilities vienna austria biopharmaceutical enable business contract manufacturing successfully completed million eur development invested vienna site germany construction biological development center bdc expansion research site biberach promoted last year investments amounted around million eur supplementing number high investments boehringer ingelheims global research development network group management report report economic position animal health boehringer ingelheim invests new antigen production center jonage france veterinary public health response growing demand medicines treat footandmouth bluetongue disease total investment project mil lion eur approximately million eur paid past financial year cash outflow financing activities amount million eur mainly comp rises tax refunds shareholders personal taxes associated groups activities amounts reported groups tax expense due commercial law regulations overall taking consideration changes due exchange rate movements valua tionrelated changes groups financial funds decreased total million eur million eur december particular due transfer cash short term securities longterm financial assets net assets position million eur change change assets intangible tangible assets financial assets fixed assets inventories trade accounts receivable receivables current assets securities cash cash equivalents current assets assets total assets equity liabilities group equity provisions pensions similar obligations tax provisions provisions accounts payable loans thereof residual term year liabilities liabilities difference capital consolidation total equity liabilities december boehringer ingelheims total assets amounted million eur increase million eur compared previous year increase mainly attributable investments tangible assets acquisitions well positive cash flow financial year inventories receivables also rose moreover positive currency effects increased balance sheet items intangible tangible fixed assets increased due acquisitions continuously high volume capital expenditure strategic expansion companys business including stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report human pharma research germany biopharmaceuticals vienna austria fremont california usa animal health france addition positive currency effects creased volume fixed assets funds previously held cash invested shortterm investments invested longterm securities together investment funds resulting cash flow course financial year longterm secu rities investments significantly increased volume longterm financial assets working capital inventories receivables rose due increased production costs result higher price levels procurement markets buildup safety stocks bio pharmaceutical contract manufacturing animal health well positive currency effects moreover trade accounts receivable rose usa reporting date due increased volume receivables wholesalers germany due increase volume receivables arising license agreements rise receivables assets sulted increased tax prepayments sales tax receivables germany mexico usa particular assets increased due higher deferred tax assets resulting tem porary differences valuations consolidated companies tax balance sheets valuations consolidated balance sheet pension provisions especially well positive market trend plan assets pensions similar obligations item also increased due currency effects equity amounted million eur december equity ratio improved around december spite higher balance sheet total addition billion eur equity pension provisions longterm liabilities also available group capital equity long term three items totaled million eur december repre senting share total assets consequently previous years longterm disposable capital continues cover intangible tangible fixed assets well working capital equity ratio pension provisions rose germany particular due decline discount rate well currency effects increase provisions correlates change level revenue since includes provisions discounts usa commissions royalty payments addition positive currency effects resulted higher tax provisions provisions volume liabilities risen due increased debt financing brazil greece china advance payments customers biopharmaceutical contract man ufacturing business liabilities shareholders positive currency effects liabilities declined mainly due release difference arising capital consolidation well deferred income net assets position likewise reflects boehringer ingelheims positive development financial year boehringer ingelheim remains soundly financed company making con siderable capital expenditure development business research activities order ensure longterm growth thus independence group management report report opportunities risks report opportunities risks opportunities risk management assessing risks context holistic opportunities risk management also endeavor take account resulting opportunities opportunity management based strategies objectives company indi vidual businesses operating business units integral part groupwide plan ning management systems responsible businesses functions bear direct responsibility early systematic identification analysis use opportunities boehringer ingelheim researchdriven biopharmaceutical company current research development activities naturally considered opportunity relevant projects al ready outlined research development chapter also consider digitalization opportunity see new technological possibilities areas research particu larly clinical development well support patients therapy current covid pandemic giving greater priority opportunity digitalization many different areas especially sales administration aim risk management system implemented boehringer ingelheim identi fy businessspecific risks early possible particularly risks jeopardize continued existence company assess reduce reasonable level means suitable measures persons responsible key businesses functions also included process calculating assessing risks groupwide risk information system ensures identified risks analyzed assessed carefully following appropri ate classification adequate risk management measures initiated implementation consistently monitored year review internal auditing performed targeted routine audits well extraordi nary audits around world addition adherence legal requirements internal group guidelines main focal points functionality systems effectiveness internal controls prevention loss assets efficiency structures processes corresponding adjustments optimizations initiated necessary individual risks key risks boehringer ingelheim exposed broken following specific categories financial risks legal risks information technology risks production environmental risks personnel risks sectorspecific risks risks identified concrete appear controllable means specific management procedures term abstract used case risks completely controlled even means targeted management procedures regardless probability occurrence stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report financial risks relevant financial risks broken follows currency risks geopolitical risks credit country specific risks well financial investment shareholding risks currency risks global orientation business activities subject risks opportunities due ex change rate volatility relation us dollar japanese yen also regard emerging markets currencies especially chinese renminbi group monitors quantifies risks regular intervals making predictable future business means relevant hedging strategies appropriate financial instruments forward exchange contracts resultant risks subsequently designated concrete con trollable therefore limited geopolitical risks business boehringer ingelheim global company adversely affected geo political developments significant risks may arise example geopolitical tensions changing economic political conditions may impact production sites sales markets global geopolitical developments constant observation boehringer ingelheim order able take appropriate measures early stage address abstract low risks maintain successful global business credit country specific risks boehringer ingelheim exposed various credit countryspecific risks result international business activities portfolio trade accounts receivable trade ac counts payable identified extraordinary risks group beyond usual level industry since start covid pandemic also compared previous years applies possible default risks receivables largely hedged economic political risks continue carefully track credit countryspecific risks position respond negative changes timely manner risks consider moderate therefore regarded concrete financial investment shareholding risks group pursues conservative investment strategy management financial assets primary objective longterm preservation real value reflected orientation portfolio mainly comprises money market bond investments results concrete controllable limited level risk financial investments net book value strategic investments related companies affected market business circumstances leads higher level volatility fair market value specific risks covered respective impairments consolidated finan cial statements group management report report opportunities risks legal risks business activities group exposed legal risks distinction made regulatory liability patent protection risks regulatory risks boehringer ingelheim exposed risks arising legal disputes proceedings well official investigations legal administrative decisions ongoing future proceedings predicted regard resultant risks abstract high liability risks marketing sale pharmaceuticals exposed potential product liability risk boehringer ingelheim currently product liability insurance companys risk profile absolutely guarantee however insurance coverage maintained reasonable cost acceptable conditions sufficient protect boehringer ingelheim claim loss potential claims losses case foreseeable product liability insurance cover partially covers specific liability risk remaining risk exposure covered provision therefore see moderate risk group furthermore product liability claims could tie substantial financial resources manage ment capacity detrimental companys image event market considers product unsafe ineffective result unexpected side effects see abstract moderate risk patent protection risks protection innovations trademark patent rights particular importance boehringer ingelheim researchdriven biopharmaceutical company commercial pro tective rights increasingly target attacks breaches taken necessary precautions allow us detect threats early stage commencing appropriate countermeasures defend legal position using legal means available us factors regarded concrete moderate risks information technology risks boehringer ingelheim uses globally networked systems core areas operations busi ness production processes well internal external communication also makes use cloudbased thirdparty systems services systems used process store transmit confidential personal data availability integrity confidentiality systems data processed thus highly significant stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report external cyberattacks manipulation systems may result loss information expertise well temporary interruptions business production processes risk considered high concrete view continuously evolving global environment growing frequency cyberattacks covid pandemic elevated risk threats attacks since people creasingly working home employees thus access sensitive data via less secure environments boehringer ingelheim countering risk means continuous process analysis improvements well preventive reactive measures helps identify ward current threats minimize potential damage production environmental risks quality management system compliance processes continuously optimized close cooperation relevant authorities order ensure compliance cgmp standards current good manufacturing practices risks area continue high significance group classified abstract boehringer ingelheim implemented riskmitigating measures past year order counter covidspecific threats production activ ities include physical segregation production teams possible obligation wear mask increase supply disinfectants inhouse initiatives testing covid status employees order protect facilitybased functions employees whose presence sitedependent asked work home order ensure supply products market implemented measures guarantee reliable highquality supplies internal external customers addi tion supplier management procurement side also involves building internal standby capacities overall represents concrete moderate risk risks areas environment health safety sustainability ehss preemptive ly minimized ensuring global adherence high safety standards appropriate emergency plans drawn possible incidents kind practiced subjected comprehensive quality testing regular intervals result measures risks classed concrete limited personnel risks boehringer ingelheim companies exposed demographic change resultant risk affected lack appropriately qualified personnel potential risk substantial impact companys business activities therefore included longterm planning process many years gained strategic significance result group management report report opportunities risks boehringer ingelheim counters risk means comprehensive personnel concept context global personnel management also presents group opportunities gardless ethnic background gender religion offer companys employees development opportunities based professional abilities social skills personal aptitudes willingness take responsibility accordance needs company view measures described risk regarded concrete moderate boehringer ingelheim likewise exposed human resources risks result covid pandemic pathogen spread would significant impact outside production activities company therefore closely monitoring situation vicinity sites also emphasizes working home using digital applications rather inperson meetings curbing employee travel large extent view measures considered concrete moderate risk industryspecific risks boehringer ingelheim subject industryspecific business risks pharmaceutical industry risks partly materialized past financial year becoming creasingly important boehringer ingelheim due effects continue classed abstract high addition loss exclusivity products established market risks associated development registration new medicines risks creasingly include changing restrictive requirements relating pricing reimbursement many sales markets frequently prices pharmaceutical products subject state monitoring regulation also price pressure cheaper generic drugs induced state reimbursement systems boehringer ingelheim keeping close eye various changes sales markets takes appropriate measures response current developments overall statement risk situation current perspective aware risks alone conjunction risks could lead lasting impairment companys assets financial earnings posi tion could jeopardize continued existence boehringer ingelheim stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report report expected developments boehringer ingelheim look back successful financial year surpassed ambitious targets terms absolute figures contribution wellbeing patients pets livestock despite volatile global economic situation able ensure companys sustainable development profitable growth continuing covid pandemic fragile global supply chains general inflation trend difficult industry environment mean continue face challenges however uncertainty past two years context global pandemic would ap pear gradually giving way predictable challenges opportunities therefore optimistic view ongoing volatility even remains difficult make forecasts coming financial year expect see ongoing global economic recovery assume vaccines medicines already approved plus therapies currently undergoing approval pro cess help curb covid pandemic strength experience past years measures implemented confident able handle temporary setbacks without encountering substantial supply problems largest source uncertainty next five years potential impact economic factors governments budget planning whether affect policymaking terms expenditure healthcare medicines assuming possible curb c ovid pandemic expect see moderate market growth prescription pharmaceuticals ever also witnessing growing global institutional efforts bring prices medicines view trend financial flexibility remains critical us order ensure longterm growth innovation animal health business following strong market growth expect see normalization market growth trend new financial year research innovation play particularly important role together business partners intend continue provide customers innovative solutions development african swine fever situation remain critical factor priorities biopharmaceu ticals business supplying market products contract manufacturing business partners increasing level capacity utilization new largescale cell culture plant vienna another core area focus expect boehringer ingelheim achieve slight yearonyear increase net sales comparable basis adjusted currency extraordinary effects consistently high rd expenditure increased line strategic focus continuing drive growth flow new products achieved goal obtaining rd external innovation part nerships continue actively pursue strategy invest external rd close investigation therapeutic benefit associated prospects success flow innovative medicines research development pipeline shows short medium longterm growth potential expect see increase rd investments new medicines intend reach new milestones research development well individual market approvals group management report report expected developments addition patent expiry attacks patents major challenges facing researchdriven pharmaceutical industry increasing amount investment rd well bigger hurdles increased costs associated product approvals also particular note previously mentioned growing cost pressure healthcare systems last two years pandemic researchdriven pharmaceutical companies displayed unprecedented level networking energy develop solutions extremely quickly thus proving societal value research innovation support policymakers additional concrete steps needed contribution pharmaceutical companies increased efficiency overall healthcare system remunerated appropriately animal health research likewise requires major investments preventive research diagnostic options conjunction long planning development cycles new products growing public cost pressure means business less predictable requires us quickly recognize seize opportunities human pharma animal health one hand contin uously monitoring adjusting costs strategies implemented measures business areas accelerate speed response changes reduce complexity organization optimize cost base way creating potential capital expenditure securing companys longterm success expect boehringer ingelheim achieve slightly lower operating income due increased level investment research development comparable basis adjusted currency extraordinary effects familyowned company boehringer ingelheims primary aim remains creation value innovation safeguards competitiveness longterm entrepreneurial independence confident achieve ambitious targets business areas thanks great innovative strength rests comprehensive portfolio pro spective products global presence support highly qualified motivated employees remain committed ambition company whole research develop innovative products human veterinary medicine bring market areas high medical need break new ground therapeutic approaches aim endeavors make new medicines available humans animals treated effectively new therapies stnemetats laicnanif detadilosnoc oiloftrop tcudorpneuronal cells connections human brainconsolidated financial statements verview selected consolidated companies consolidated balance sheet consolidated profit loss statement consolidated cash flow statement statement changes group equity n otes consolidated financial statements independent auditors report stnemetats laicnanif detadilosnoc oiloftrop tcudorp boehringer ingelheim annual report overview selected consolidated companies ch boehringer sohn ag co kg ingelheim rhein boehringer ingelheim vetmedica gmbh ingelheim rhein argentina italy p taiwan germany p r boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim corporate argentina sa buenos aires italia spa milan taiwan co ltd taipei center gmbh ingelheim rhein australia japan r thailand boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim pharma australia pty ltd north ryde japan co ltd tokyo thailand limited bangkok gmbh co kg ingelheim rhein boehringer ingelheim microparts belgium p r mexico p usa p r gmbh dortmund boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim venture fund belgium sa brussels mxico sa de cv mexico city usa inc wilmington delaware gmbh ingelheim rhein boehringer ingelheim veterinary boehringer ingelheim medicine belgium evergem netherlands r vietnam biopharmaceuticals gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim vietnam ltd brazil p netherlands bv alkmaar ho chi minh city boehringer ingelheim middle east africa gmbh boehringer ingelheim animal health ingelheim rhein brasil ltda paulo new zealand p boehringer ingelheim animal health canada new zealand limited auckland boehringer ingelheim animal health canada inc burlington philippines boehringer ingelheim animal health china p r philippines inc makati city nanchang boehringer ingelheim animal health co ltd nanchang puerto rico p boehringer ingelheim animal boehringer ingelheim animal health health shanghai co ltd puerto rico llc barceloneta shanghai boehringer ingelheim animal south africa health operations china co ltd taizhou boehringer ingelheim animal health boehringer ingelheim vetmedica south africa pty ltd midrand china co ltd taizhou gauteng denmark p south korea boehringer ingelheim animal health boehringer ingelheim animal health denmark copenhagen korea ltd seoul france p r spain boehringer ingelheim animal health boehringer ingelheim animal health france lyon espaa sa barcelona great britain p boehringer ingelheim animal health uk limited bracknell distribution p production r research development consolidated financial statements overview selected consolidated companies ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim international gmbh ingelheim rhein argentina denmark japan p r serbia boehringer ingelheim sa boehringer ingelheim danmark nippon boehringer ingelheim co boehringer ingelheim serbia doo buenos aires copenhagen ltd tokyo beograd belgrade boehringer ingelheim seiyaku australia ecuador yamagata south africa boehringer ingelheim pty ltd boehringer ingelheim del ecuador ingelheim pharmaceuticals north ryde cia ltda quito mexico p proprietary ltd midrand gauteng boehringer ingelheim mexico sa de austria p r finland cv mexico city south korea boehringer ingelheim rcv boehringer ingelheim finland ky boehringer ingelheim vetmedica sa boehringer ingelheim korea ltd gmbh co kg vienna espoo de cv guadalajara seoul boehringer ingelheim promeco sa forschungsinstitut fr molekulare de cv mexico city pathologie gesellschaft mbh vienna france spain p viratherapeutics gmbh rum boehringer ingelheim france sas netherlands boehringer ingelheim espaa sa paris barcelona belgium boehringer ingelheim bv alkmaar scs boehringer ingelheim commv germany r sweden brussels boehringer ingelheim new zealand boehringer ingelheim aktiebolag therapeutics gmbh ochsenhausen boehringer ingelheim nz ltd stockholm brazil p auckland boehringer ingelheim brasl great britain switzerland r qumica e farmaceutica ltda boehringer ingelheim ltd norway boehringer ingelheim schweiz paulo bracknell boehringer ingelheim norway ks gmbh basel asker nbetherapeutics ag basel canada greece p amal therapeutics sa geneva peru boehringer ingelheim canada ltd boehringer ingelheim ellas single toronto member sa athens boehringer ingelheim peru sac taiwan lima boehringer ingelheim taiwan ltd chile hong kong taipei philippines boehringer ingelheim ltda boehringer ingelheim hong kong santiago de chile ltd hong kong boehringer ingelheim philippines thailand inc manila boehringer ingelheim thai ltd china p india bangkok poland boehringer ingelheim shanghai boehringer ingelheim india private pharmaceuticals co ltd shanghai ltd mumbai boehringer ingelheim sp z oo turkey boehringer ingelheim warsaw boehringer ingelheim ila ticaret biopharmaceuticals china co ltd indonesia p istanbul shanghai portugal pt boehringer ingelheim indonesia boehringer ingelheim china jakarta boehringer ingelheim portugal lda usa p r investment co ltd shanghai lisbon bi x ehealth technology shanghai boehringer ingelheim co ltd shanghai isr ba oe el hringer ingelheim israel ltd russia p wh ila mrm ina gc te ou nt dca el ls w ac colombia tel aviv ooo boehringer ingelheim moscow boehringer ingelheim fremont inc wilmington delaware boehringer ingelheim sa italy p saudi arabia boehringer ingelheim usa santa f de bogot corporation wilmington delaware boehringer ingelheim italia spa boehringer ingelheim saudi arabia czech republic milan trading riyadh vietnam bidachem spa fornovo giovanni boehringer ingelheim spol sro boehringer ingelheim animal health prague vietnam limited liability company ho chi minh city oiloftrop tcudorp boehringer ingelheim annual report consolidated balance sheet assets million eur notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets securities cash cash equivalents current assets prepaid expenses deferred tax assets exceeding amount plan assets total assets equity liabilities million eur notes shareholders capital group reserves balance sheet currency conversion difference equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions accounts payable loans liabilities deferred income deferred tax liabillities total equity liabilities explanations see relevant section notes consolidated financial statements consolidated financial statements consolidated balance sheet consolidated profit loss statement consolidated profit loss statement million eur notes net sales changes finished goods work process work capitalized operating income total revenues cost materials personnel expenses amortization intangible assets depreciation tangible assets operating expenses operating income financial income holding income income taxes income taxes income taxes net income noncontrolling interests group profit explanations see relevant section notes consolidated financial statements due legal requirements shareholders personal taxes arising group business activities shown withdrawals group reserves oiloftrop tcudorp boehringer ingelheim annual report consolidated cash flow statement million eur income taxes including noncontrolling interests amortization depreciation writedowns reversal writedowns intangible tangible financial assets change provisions pensions similar obligations including change plan assets change provisions noncash income expenses gain disposals consolidated companies gains losses disposals fixed assets grants received change inventories change accounts receivable assets related investing financing activities change accounts payable liabilities related investing financing activities interest income interest expenses income investments income expenses income taxes income taxes paid cash flow operating activities payments acquire intangible fixed assets payments acquire tangible fixed assets payments acquire financial fixed assets payments acquire plan assets payments relating purchase price adjustments consolidated entities investments consolidated companies proceeds disposals intangible fixed assets proceeds disposals tangible fixed assets proceeds disposals financial fixed assets proceeds disposals consolidated entities interest received income dividends cash flow investing activities consolidated financial statements consolidated cash flow statement statement changes group equity consolidated cash flow statement continued million eur cash receipts grants interest paid cash receipts shareholders parent company cash payments shareholders parent company proceeds loans cash repayments loans cash flow financing activities change financial funds cash relevant transactions change financial funds due exchange rate movements valuation adjustments financial funds financial funds line mainly contains shareholders personal taxes arising group business activities according legal requirements included groups tax expenses cash cash equivalents securities within current assets source funds use funds statement changes group equity balance sheet equity currency attributable non shareholders group conversion parent controlling million eur capital reserves difference company interests group equity balance withdrawals net income currency effects balance withdrawals net income reduction recognition deferred tax liabilities recognized directly equity changes consolidated companies currency effects balance shareholders capital consists equity ch boehringer sohn ag co kg ch boehringer sohn grundstcksverwaltung gmbh co kg shareholders capital consists limited partners capital contribution shareholders personal taxes arising group business activities shown withdrawals group reserves oiloftrop tcudorp boehringer ingelheim annual report notes consolidated f inancial statements principles methods general principles consolidated financial statements boehringer ingelheim financial year prepared accordance section german commercial code hgb line legal requirements prepare consolidated financial statements section et seq hgb accordance section hgb consolidated financial statements consist consolidated balance sheet consolidated profit loss statement notes consolidated financial statements consolidated cash flow statement statement changes equity consolidated financial statements prepared euros accordance section conjunction section hgb improve clarity transparency consolidated financial statements subtotals added con solidated profit loss statement furthermore individual items consolidated balance sheet c onsolidated profit loss statement combined items presented explained separately notes additional disclosures required individual items also found notes registry information parent company registered name ch boehringer sohn ag co kg headquarters ingelheim rhein commercial register mainz district court number hra information group consolidated companies parent company boehringer ingelheim group ch boehringer sohn ag co kg ingelheim rhein boehringer ag ingelheim rhein sole unlimited partner company boehringer ingelheim group consists total affiliated companies germany abroad sub sidiaries included consolidated financial statements ch boehringer sohn ag co kg full cons olidation rules ch boehringer sohn grundstcksverwaltung gmbh co kg special purpose entity ch boehringer sohn ag co kg bears majority risks opportunities economic terms ch boehringer sohn ag co kg holds majority voting rights subsidiaries either directly indirectly consolidated financial statements notes consolidated f inancial statements accordance section hgb subsidiaries included consolidation reporting year individually collectively insignificant groups net assets financial earnings position total amount sales equity net income year subsidiaries included consolidation accounts less one percent aggregated group financial statements totals two subsidiaries ongoing restrictions control due terms articles association accordance section hgb companies consolidated either total number subsidiaries increased four compared previous year nine companies acquired two companies lost separate legal identities merger two affiliated companies liquidated one affiliated company sold following subsidiaries exempted reporting disclosure obligations section hgb boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim europe gmbh ingelheim rhein boehringer ingelheim finanzierungs gmbh ingelheim rhein boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim rhein boehringer ingelheim grundstcksgmbh ingelheim rhein boehringer ingelheim rd beteiligungs gmbh ingelheim rhein boehringer ingelheim animal health france participations gmbh ingelheim rhein boehringer ingelheim finanzinvest gmbh ingelheim rhein following subsidiaries exempted reporting disclosure obligations section b hgb ch boehringer sohn ag co kg ingelheim rhein ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim pharma gmbh co kg ingelheim rhein boehringer ingelheim veterinary research center gmbh co kg ingelheim rhein boehringer ingelheim participates one joint venture included consolidated financial state ments using either proportionate method equity method since material furthermore boehringer ingelheim holds interest associated companies accounted using equity method either due lack significance resulting effect groups total assets net income less one percent oiloftrop tcudorp boehringer ingelheim annual report consolidation methods inventories fixed assets receivables liabilities income expense items transactions com panies included consolidation eliminated part debt consolidation procedures accordance section hgb procedures eliminate intercompany profits accordance section hgb income expenses consolidation procedures accordance section hgb revaluation method applied including subsidiaries consolidation first time accordance section hgb companies included consolidation first time date com pany became subsidiary book value shares held parent company offset corresponding equity subsidiary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time consolidation remaining positive bal ance recorded goodwill remaining negative balance recorded difference capital consolidation currency translation assets liabilities resulting foreign currency transactions translated using average spot exchange rate balance sheet date realization principle section conjunction section half sentence hgb historical cost principle section conjunction section sentence hgb applied items remaining term one year consolidated financial statements financial statements foreign subsidiaries domiciled state outside eurozone denominated foreign currency converted euros using modified closing rate method accordance section hgb using modified closing rate method asset liability items annual financial statements prepared foreign currency translated euros using average spot exchange rate balance sheet date exception equity translated using historical rate items included profit loss statement translated euros using annual average rate resulting translation differences reported within consoli dated equity reserves balance sheet currency conversion difference exchange rates groups important currencies changed follows reporting year basis eur spot rate average rate us dollar japanese yen chinese renminbi consolidated financial statements notes consolidated f inancial statements accounting policies fixed assets acquired tangible intangible assets carried cost less scheduled straightline amortization depreciation determined consideration technical economic circumstances based following useful lives goodwill years intangible assets years buildings years technical facilities machines years facilities operating equipment years straightline depreciation amortization used consolidated financial statements additional write downs recorded reflect impairments value assets considered permanently impaired manufacturing costs include materials labor manufacturing costs appropriate portion materials labor overheads depreciation fixed assets extent caused production manufacturing costs include financing costs capitalized intangible assets finite useful lives current financial year goodwill increased overall million eur due acquisition three companies amount million eur related acquisition nbe therapeutics sa financial assets primarily include investment securities shareholder rights loans carried lower cost fair market value impaired event reasons impairment losses recognized previous financial years longer applicable corresponding reversals recorded current assets prepaid expenses deferred income exceeding amount plan assets inventories carried lower cost fair market value raw materials consumables supplies capitalized lower average acquisition prices fair market value balance sheet date finished goods work progress measured manufacturing cost basis individual calculations taking account directly attributable costs materials direct labor costs special direct costs appropriate share material production overhead costs productionrelated depreciation oiloftrop tcudorp boehringer ingelheim annual report goods resale valued lower either acquisition cost fair market value identifiable risks inventories arising aboveaverage storage periods diminished marketability lower replacement costs taken account recording appropriate valuation adjustments inventories valued lossfree deductions made expected sales prices reflect costs yet incurred receivables assets recognized cost less allowances specific risks general credit risk low interest noninterestbearing receivables term one year discounted securities classified current assets solely include securities recognized lower cost fair market value stock market price reporting date cash cash equivalents consisting cash balances banks checks recognized lower cost fair market value prepaid expenses recorded accordance section hgb include expenses paid advance respect defined period time balance sheet date deferred income recorded accordance section hgb includes proceeds represent income respect defined period time balance sheet date fair market value pension plan assets corresponding present value pension obligations offset according german gaap exceeding amount plan assets capitalized separately group reserves group reserves include retained earnings consolidated subsidiaries prior current years consoli dation entries affect earnings difference capital consolidation difference capital consolidation reported december primarily result business swap boehringer ingelheims consumer healthcare business sanofis animal health business completed january resulted difference capital consolidation million eur difference amor tized estimated period years remaining balance difference amounted million eur december difference capital consolidation primarily influenced current year release million eur furthermore difference capital consolidation decreased million eur due sale us company newport laboratories inc income release difference arising capital consolidation included operating income release made corresponding amortization assets acquired company identified purchase price allocation previously recognized companys balance sheet consolidated financial statements notes consolidated f inancial statements provisions tax provisions provisions include uncertain liabilities expected losses executory contracts carried amount required settle obligation based reasonable prudent commercial judgment including future cost price increases provisions remaining maturity one year discounted using matchedterm average market interest rate case pension provisions interest rate results average market interest rate last ten years case provisions average market interest rate last seven years accordance rckstellungsabzinsungsverordnung german regulation discounting provisions since environmental protection measures cases expected result permanent burden relevant pro visions calculated basis perpetual annuity taking consideration cost price increases well interest effects valuation method adjusted year review since method previously used longer gives true fair view net assets earnings position group consideration declining interest rates rising inflation rates instead average rate change consumer price index past ten years current costs adjusted inflation basis average rate change producer price index industrial products since introduction euro ultimate forward rate ufr provided european insurance occupational pensions authority eiopa used discounting instead sevenyear average interest rate term years accordance rckstellungsabzinsungsverordnung german regulation discounting provisions effects valuation adjustment balance sheet profit loss statement explained note accounts payable accounts payable loans recognized settlement amount deferred taxes calculate deferred taxes arising temporary quasipermanent differences carrying amounts assets liabilities prepaid expenses deferred income commercial balance sheet carrying amounts tax purposes tax loss carryforwards amounts resulting tax benefits expenses time differences reverse measured using tax rates specific respective consolidated company de ferred tax balances discounted differences due consolidation measures accordance sections hgb also measured using companyspecific tax rates applicable time expected reversal difference deferred tax assets loss carryforwards taken account likely used within next five years deferred tax assets liabilities reported without offsetting oiloftrop tcudorp boehringer ingelheim annual report notes consolidated balance sheet intangible assets acquired concessions advance million eur similar rights goodwill payments total acquisition manufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated amortization balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value consolidated financial statements notes consolidated f inancial statements tangible assets advance technical facilities payments land facilities operating construction million eur buildings machines equipment progress total acquisition manufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value oiloftrop tcudorp boehringer ingelheim annual report financial assets investments loans investments loans affiliated affiliated related related investment million eur companies companies companies companies securities loans total acquisition manufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value previous year loans item include loans shareholders consolidated financial statements notes consolidated f inancial statements inventories million eur raw materials supplies unfinished goods finished goods goods resale advance payments suppliers accounts receivable assets residual term residual term million eur year year trade accounts receivable receivables affiliated companies receivables related companies assets assets item includes receivables shareholders million eur previous year million eur receivables affiliated companies almost exclusively consist receivables loans receivables related companies primarily consist trade accounts receivable provisions million eur pension provisions similar obligations tax provisions provisions oiloftrop tcudorp boehringer ingelheim annual report provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data germany example g mortality tables published prof dr klaus heubeck adjusted groupspecific death probabilities invalidity rates pension obligations signifi cant countries calculated basis following actuarial parameters december germany usa discount rate salary increase pension increase discount rates determined reference average market rates year maturities accordance german regulation discounting provisions march interest rates used discount significant foreign pension obligations usa determined comparable parameters line german regulation discounting provisions march difference calculated accordance section hgb amounts million eur previous year million eur plan assets intended solely cover pension similar obligations unavailable creditors plan assets defined section sentence hgb measured fair market value essentially derived stock market prices offset underlying pension similar obligations fair market value plan assets balance sheet date million eur related amount pension obligations similar obligations million eur tax provisions tax provisions also include provisions double taxation risks resulted following implementation action plans organisation economic cooperation development oecd part international initiative known action plan base erosion profit shifting beps consolidated financial statements notes consolidated f inancial statements provisions provisions mainly include provisions discounts guarantees personnelrelated provisions provisions outstanding invoices provisions litigation legal claims compensation damages environmental provisions please refer comments impacts change valuation method environmental provisions note use new method resulted million eur reduction related provisions december relative situation december reduced operating income past financial year million eur oneoff effect financial income increased million eur accounts payable residual term residual term less thereof less million eur year year years year bank loans accounts payable thereof trade accounts payable advance payments received accounts payable affiliated companies accounts payable related companies liabilities thereof taxes million eur social security liabilities million eur previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders million eur previous year million eur presented within liabilities item accounts payable affiliated companies include loans amounting million eur previous year million eur trade accounts payable amounting million eur previous year million eur oiloftrop tcudorp boehringer ingelheim annual report n otes consolidated profit loss statement structure consolidated profit loss statement based total cost format taxes included operating expenses net sales business million eur human pharma animal health biopharmaceutical contract manufacturing sales discontinued operations region million eur americas europe asia australia africa aaa operating income operating income includes income currency translation million eur previous year million eur cost materials million eur costs raw material supplies goods resale expenditure services consolidated financial statements notes consolidated f inancial statements personnel expenses million eur wages salaries social benefits retirement benefits thereof retirement benefits interest effects measurement provisions pensions similar obligations shown financial income average headcount production marketing sales research development administration apprentices amortization intangible assets depreciation tangible assets amortization intangible assets depreciation tangible assets include impairment losses million eur previous year million eur operating expenses operating expenses include expenses currency translation million eur previous year mil lion eur addition items included operating expenses mainly charges made record provisions thirdparty services research development medicine marketing purposes administrative expenses fees contributions commissions rent freight expenses repairs carried third parties well legal risks restructuring oiloftrop tcudorp boehringer ingelheim annual report financial income million eur interest expenses similar expenses amortization loss disposal financial fixed assets shortterm investments income investment securities longterm loans interest income similar income interest expenses similar expenses item includes interest result provisions pensions similar obligations provisions amount million eur previous year million eur well interest expenses similar expenses amount million eur previous year million eur gains losses plan assets interest expense relating pension similar obligations offset accor dance section sentence hgb total million eur earnings plan assets million eur interest expense relating pension similar obligations included interest expenses similar expenses holding income million eur writedowns financial assets writeups financial assets income related companies thereof disposal related companies income taxes million eur current income taxes deferred taxes current income taxes primarily include corporation trade tax expenses consolidated companies consolidated financial statements notes consolidated f inancial statements total balance deferred tax assets balance sheet date amounted million eur previous year million eur deferred tax assets primarily arise difference carrying amounts provisions pension obligations discounts tax goodwill intangible assets inventories tangible assets deferred tax lia bilities million eur previous year million eur recorded primarily relate differences carrying amounts intangible assets tangible assets inventories provisions net income net income positively influenced nonperiod income primarily reversal provisions million eur previous year million eur negatively influenced nonperiod expenses particular additional expenses related provisions million eur previous year million eur notes consolidated cash flow statement consolidated cash flow statement shows changes financial funds boehringer ingelheim group resulting cash inflows outflows reporting year financial funds contain cash cash equivalents well secu rities converted cash shortterm changes balance sheet items affiliated companies included translated using average rates year balance sheet financial funds carried spot rate effect exchange rate changes financial funds shown separately financial funds december comprised following items million eur cash cash equivalents securities financial funds included million eur restricted funds balance sheet date oiloftrop tcudorp boehringer ingelheim annual report disclosures contingent liabilities million eur liabilities guarantees warranties granting securities thirdparty liabilities risk utilization contingent liabilities assessed low account good net assets financial earnings position financial commitments offbalance sheet transactions million eur rental lease obligations residual financial commitments within rental lease obligations million eur previous year million eur relate longterm rental agree ments subsidiaries included consolidation purpose lease agreements lower capital commitment compared buying property absence resale risk risks could arise term lease possible continue utilize properties fully indications time residual financial commitments include investments future effects cash flows million eur previous year million eur derivative financial instruments valuation units due extensive international structure boehringer ingelheim group highly dependent developments worlds currencies interest rates hedge risks particularly emerging delivery goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks use derivative financial instruments organizational processes set internal guidelines strict separation trading processing documentation control consolidated financial statements notes consolidated f inancial statements risk positions regularly tracked analyzed measured special groupwide financial report positions en tered periodically reevaluated monitored fair value derivative financial instruments calculated using generally accepted market valuation methods currency forwards based present value method taking account market data balance sheet date provisions million eur recognized currency forwards included hedge accounting negative fair value within one currency balance sheet date line imparity principle positive fair values within one currency recognized balance sheet date derivative financial instruments included hedge accounting valuation units follows nominal value fair value million eur foreign exchange forward contracts extent requirements hedge accounting foreign currency forward exchange contracts highly probable forecast transactions accordance section hgb met foreign currency forward exchange contracts recognized balance sheet line net hedge presentation method following accounting policies apply recognition valuation units accordance section hgb economic hedges accounted financial statements use valuation units valuation units recognized foreign currency based net amount highly probable forecasted transactions currency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales purchases derived company planning expost analysis planning shown planned transactions highly probable opposing changes value hedged item hedging instrument fully offset critical terms turity nominal amount foreign currency match effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure prospective retrospective effectiveness hedges excess amounts hedging transactions included valuation units oiloftrop tcudorp boehringer ingelheim annual report december hedges highly probable forecasted net cash flows recognized follows january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december usd january may jpy net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy january may net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd consolidated financial statements notes consolidated f inancial statements furthermore december valuation units foreign currency receivables recognized follows receivables million eur foreign exchange forward contracts million eur nominal value nominal value fair value rub rub rub december valuation units foreign currency receivables resulting loans recognized follows receivables million eur foreign exchange forward contracts million eur nominal value nominal value fair value cad cad cad chf chf chf cny cny cny mxn mxn mxn rub rub rub thb thb thb usd usd usd amount hedged foreign currency risk correlates relative change exchange rate plan ning date realization date forecasted transactions currencies appreciate depreciate euro would foreign currency risk million eur without hedging oiloftrop tcudorp boehringer ingelheim annual report research development expenses million eur research development expenses noncapitalized research development expenses include among items costs associated clinical studies total auditor fees total fees charged group auditor financial year amounted million eur million eur relates audits financial statements million eur assurance services million eur tax advisory services million eur services subsequent events since end financial year become aware events material significance group could lead reappraisal net assets financial earnings position shareholdings list companies included consolidated financial statements complete list shareholdings presented accordance section hgb included audited consolidated financial statements submitted german federal gazette ingelheim rhein march boehringer ag board managing directors hubertus von baumbach carinne knochebrouillon dr michel pairet jean scheftsik de szolnok michael schmelmer consolidated financial statements independent auditors report independent auditors report ch boehringer sohn ag co kg ingelheim rhein qualified audit opinion consolidated financial statements audit opinion group management report audited consolidated financial statements ch boehringer sohn ag co kg ingelheim rhein subsidiaries group comprise consolidated balance sheet december consolidated profit loss statement cash flow statement statement changes group equity financial year january december notes consolidated financial statements including recognition measurement policies presented therein addition audited group management report ch boehringer sohn ag co kg financial year january december opinion basis knowledge obtained audit except effects matter described section basis qualified audit opinion consolidated financial statements audit opinion group management report accompanying consolidated financial statements comply material respects requirements german commercial law give true fair view assets liabilities financial position group december financial performance financial year january december compliance german legally required accounting principles accompanying group management report whole provides appropriate view groups position material respects group management report consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future development pursuant section sentence hgb handelsgesetzbuch german commercial code declare except qualification audit opinion consolidated financial statements mentioned audit led reservations relating legal compliance consolidated financial statements group management report basis qualified opinion consolidated financial statements audit opinion group management report contrary section number letters b hgb total remuneration granted members former members board managing directors well pension provisions recognized recognized former members board managing directors disclosed notes consolidated financial statements conducted audit consolidated financial statements group management report accordance section hgb compliance german generally accepted standards financial statement audits promulgated institut der wirtschaftsprfer institute public auditors germany idw responsibilities requirements principles described auditors responsibilities audit consolidated financial statements group management report section auditors report inde pendent group entities accordance requirements german commercial professional law fulfilled german professional responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinions consolidated financial statements group management report oiloftrop tcudorp boehringer ingelheim annual report information management responsible information information comprises annual report ex ception audited consolidated financial statements group management report auditor 's report opinions consolidated financial statements group management report cover information consequently express opinion form assurance conclusion thereon connection audit responsibility read information consider whether information materially inconsistent consolidated financial statements group management report audited content knowledge obtained audit otherwise appears materially misstated responsibilities management consolidated financial statements group management report management responsible preparation consolidated financial statements comply material spects requirements german commercial law consolidated financial statements compliance german legally required accounting principles give true fair view assets liabilities financial position financial performance group addition management responsible internal control accordance german legally required accounting principles determined necessary enable preparation consolidated financial statements free material misstatement whether due fraud error preparing consolidated financial statements management responsible assessing groups ability con tinue going concern also responsibility disclosing applicable matters related going concern addition responsible financial reporting based going concern basis accounting provided actual legal circumstances conflict therewith furthermore management responsible preparation group management report whole provides appropriate view groups position material respects consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future development addition management responsible arrangements measures systems considered necessary enable preparation group management report accordance applicable german legal requirements able provide sufficient appropriate evidence assertions group management report consolidated financial statements independent auditors report auditors responsibilities audit consolidated financial statements group management report objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error whether group management report whole provides appropriate view groups position material respects consistent consolidated financial statements knowledge obtained audit complies german legal requirements appro priately presents opportunities risks future development well issue auditors report includes opinions consolidated financial statements group management report reasonable assurance high level assurance guarantee audit conducted accordance section hgb compliance german generally accepted standards financial statement audits pro mulgated institut der wirtschaftsprfer idw always detect material misstatement misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial statements group management report exercise professional judgment maintain professional skepticism throughout audit also identify assess risks material misstatement consolidated financial statements group man agement report whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinions risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal controls obtain understanding internal control relevant audit consolidated financial statements arrangements measures systems relevant audit group management report order design audit procedures appropriate circumstances purpose expressing opinion effec tiveness systems evaluate appropriateness accounting policies used management reasonableness estimates made management related disclosures conclude appropriateness managements use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast signif icant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial state ments group management report disclosures inadequate modify respective opinions conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease able continue going concern oiloftrop tcudorp boehringer ingelheim annual report evaluate overall presentation structure content consolidated financial statements including dis closures whether consolidated financial statements present underlying transactions events manner consolidated financial statements give true fair view assets liabilities financial position financial performance group compliance german legally required accounting principles obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express audit opinions consolidated financial statements group management report responsible direction supervision performance group audit remain solely sponsible audit opinions evaluate consistency group management report consolidated financial statements conformity german law view groups position provides perform audit procedures prospective information presented management group management port basis sufficient appropriate audit evidence evaluate particular significant assumptions used management basis prospective information evaluate proper derivation prospective information assumptions express separate opinion prospective information assumptions used basis substantial unavoidable risk future events differ materially prospective information communicate charged governance regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit frankfurt main march kpmg ag wirtschaftsprfungsgesellschaft original german version signed kneisel bernau wirtschaftsprfer wirtschaftsprferin german public auditor german public auditor consolidated financial statements independent auditors report oiloftrop tcudorpbronchial cancer several cancer cells microvilli attacked tlymphocytesproduct portfolio selection human pharmaceuticals respiratory diseases cardiovascular metabolic diseases oncology diseases central nervous system infectious diseases animal health livestock swine livestock cattleruminants livestock poultry veterinary public health vph companion animals horses companion animals pets oiloftrop tcudorp boehringer ingelheim annual report respiratory diseases respiratory diseases common chronic obstruc bronchial asthma tive pulmonary disease copd bronchial asthma among prevalent chronic diseases frequent bronchial asthma chronic inflammatory disorder cause morbidity premature deaths worldwide airways inflammation accompanied airway hyperresponsiveness leads narrowing idiopathic pulmonary fibrosis ipf rare disease airways recurrent episodes wheezing breathless severely debilitating ultimately lethal ness coughing symptoms occur particularly night early hours morning known asthma triggered genetic environmental copd factors eg allergens viral infections unlike copd asthma occur early childhood also copd chronic disease lungs causes cough present adolescents adults asthma often ing excessive mucus production dyspnea ulti estimated easytomanage condition however mately destroys lung tissue alveoli thus gas almost one two patients asthma still experience exchange affected leads limitation symptoms receiving maintenance therapy putting airflow causing shortness breath respira increased risk potentially lifethreatening asthma tory symptoms airflow limitation partially exacerbations addition patients often adjust daily reversible usually worsens time leading dis lives accommodate conditions avoid physical ability ultimately death symptoms excess exertion daytoday activities negative cough breathlessness main reasons copd impact quality life stressful patients lung emphysema chronic bronchitis main manifestations copd copd caused continuous damage lungs result ing inhaling pollutants primarily cigarette smoke however factors also need considered includ ing indoor outdoor air pollution course copd disease occurs second half humans life characterized accelerated loss lung function compared normal ageing occasional sudden worsening symptoms function referred acute exacerbations lead downward spiral worsening symptoms thus inactivity product portfolio human pharmaceuticals indications brand names active ingredients maintenance treatment patients copd chronic obstructive spiriva including chronic bronchitis emphysema pulmonary disease spiriva handihaler maintenance treatment associated dyspnoea copd spiriva respimat tiotropium bromide prevention exacerbations addon maintenance bronchodilator treatment patients aged six years older severe asthma experienced one severe asthma exacer bations past year piriva respimat approved use asthma eu japan usa many countries label varies country please refer local bronchial asthma spiriva respimat tiotropium bromide product information chronic obstructive spiolto respimat maintenance treatment airflow obstruction pulmonary disease stiolto respimat tiotropium bromide patients chronic obstructive pulmonary disease copd inspiolto respimat olodaterol hydrochloride copd chronic obstructive pulmonary disease maintenance treatment patients chronic copd striverdi respimat olodaterol hydrochloride obstructive pulmonary disease copd combination shortacting anticholin ergic reversible broncho betaadrenergic management reversible spasms associated bronchospasms associated obstructive airway obstructive airway ipratropium bromide diseases patients requiring one bron diseases combivent respimat salbutamol sulphate chodilator chronic obstructive pulmonary disease copd prevention treatment shortness breath patients chronic obstructive pulmonary disease chronic bronchitis copd mild moderate bronchial asthma adulthood childhood supplement beta bronchial asthma atrovent ipratropium bromide agonists cases acute asthma prevention treatment symptoms chronic berodual obstructive airway disorders reversible airflow chronic obstructive bronchodual ipratropium bromide limitation bronchial asthma especially airway disorders duovent fenoterol hydrobromide chronic bronchitis without emphysema oiloftrop tcudorp boehringer ingelheim annual report respiratory diseases continued idiopathic pulmonary fibrosis ipf ssc affects lungs cause interstitial lung disease ild known sscild key driver mor ipf chronic progressive lung disease associated tality among people ssc accounting approximately markedly reduced life span affecting many one third deaths people per worldwide ipf character ized progressive scarring lung tissue loss lung function time development scarred tissue chronic fibrosing interstitial lung called fibrosis time tissue thickens stiff diseases ilds progressive ens scarring lungs lose ability take phenotype beyond idiopathic pulmonary transfer oxygen bloodstream vital organs fibrosis ipf get enough oxygen result individuals ipf experience shortness breath even resting interstitial lung diseases heterogeneous group often difficulty coping demands everyday mostly rare conditions lung run life due limited physical capacity risk developing pulmonary fibrosis fibrosis pathological multiplication connective tissue lead acute ipf exacerbations defined rapid deteriora ing usually chronic irreversible scarring lung tions symptoms lung function within days weeks tissue course interstitial lung disease may develop events occur point course progressive fibrosing ild leading decline func disease even first presentation associated tion associated increased morbidity mortality high mortality patients ipf risk acute ipf idiopathic pulmonary fibrosis ipf phenotype exacerbations chronic fibrosing ild course disease symp toms similar chronic pfilds despite underlying ild diagnosis average ild patients systemic sclerosis associated interstitial develop progressive pulmonary fibrosis lung disease sscild systemic sclerosis ssc also known scleroderma rare incurable autoimmune disease affecting connective tissue disease estimated affect people every europe million worldwide ssc impacts four times many women men onset disease typically occurs young age years cause scarring fibrosis skin well major organs heart lungs digestive tract kidneys lifethreatening complica tions approximately patients develop significant pulmonary involvement within three years diagnosis product portfolio human pharmaceuticals indications brand names active ingredients symptomatic treatment acute asthma attacks prophylaxis exerciseinduced asthma bronchiale symptomatic treatment allergic non allergic asthma bronchiale conditions reversible airway narrowing eg chronic obstructive bronchial asthma berotec fenoterol hydrobromide bronchitis bronchial asthma prophylactic treatment patients bronchial asthma prophylaxis symptomatic treatment allergic rhinitis alesion epinastine hydrochloride allergic rhinitis idiopathic pulmonary fibrosis ipf countries treatment systemic sclerosis patients idiopathic pulmonary fibrosis ipf associated interstitial lung disease sscild countries therapy sscild slow rate decline pulmonary function chronic fibrosing interstitial lung diseases countries treatment ilds progressive chronic fibrosing interstitial lung diseases ilds phenotype ofev nintedanib progressive phenotype beyond ipf oiloftrop tcudorp boehringer ingelheim annual report cardiovascular etabolic diseases cardiovascular disease cv including heart disease atrial fibrillation stroke major global health concern leading cause death disability worldwide currently atrial fibrillation af common sustained heart responsible nearly one three deaths worldwide one rhythm condition affecting approximately total key risk factor developing cardiovascular disease population one four adults develops af presence diabetes people type diabetes two lifetime patients af higher risk developing four times likely develop cardiovascular disease blood clots upper left heart chamber people without diabetes result life cause stroke clot breaks loose travels expectancy years shorter proper control brain af leads fivefold increase risk stroke diabetes treatable risk factors like heart failure resulting three million patients worldwide suffering therefore vital prevention cardiovascular events afrelated strokes year patients af risk stroke reduced appropriate anticoagulation therapy stroke stroke rapidly developing loss brain functions prevention treatment caused disrupted blood flow affected brain venous thromboembolism tissue due ischemia lack blood supply caused thrombosis embolism due bleeding venous thromboembolism vte umbrella term hemorrhagic stroke result affected area encompasses deep vein thrombosis dvt pulmo brain unable function damage quickly nary embolism pe dvt occurs thrombus blood comes permanent untreated stroke acute event clot forms deep vein commonly leg requiring emergency diagnosis intervention world partially completely blocks flow blood wide stroke one leading causes death thrombus grows portion may break away main longterm disability clot travel circulatory system lungs lodging blood clot arteries lung called symptoms transient ischemic attack tia similar pe vte serious disorder potentially fatal con stroke last minutes hours sequences result permanent neurological damage tia may precede stroke emergency medical care subse patients undergoing orthopedic surgery consider quent preventive treatment may necessary able risk developing dvt chronic venous insuffi ciency pulmonary hypertension may develop longer term product portfolio human pharmaceuticals indications brand names active ingredients prevention strokes blood clots patients atrial fibrillation stroke prevention primary prevention venous thrombo embolic atrial fibrillation events vte adults elective total hip knee replacement surgery primary prevention venous thromboembolic treatment deep vein thrombosis dvt events orthopedic pulmonary embolism pe secondary prevention surgery recurrent dvt pe adults treatment secondary pradaxa treatment venous thromboembolic events vte prevention venous pradaxar prevention recurrent vte pediatric patients thromboembolic events prazaxa dabigatran etexilate birth less years age praxbind specific reversal agent dabigatran indicated adult patients treated pradaxa dabigatran etexilate rapid reversal specific reversal anticoagulant effects required emergency pradaxa surgery urgent procedures lifethreatening dabigatran etexilate praxbind idarucizumab uncontrolled bleeding treatment hypertension reduction risk myocardial infarction heart attack stroke death cardiovascular cv causes patients years age older high risk developing major cv events unable take ace inhibitors us reduction cardiovascular morbidity patients manifest atherothrombotic cardiovascu hypertension lar disease history coronary heart disease stroke peripheral arterial disease patients type cardiovascular morbidity diabetes mellitus documented target organ mortality prevention micardis telmisartan damage eu treatment hypertension alone antihy pertensive agents lower blood pressure lowering blood pressure reduces risk fatal nonfatal cardiovascular events primarily strokes myocar dial infarctions indicated initial therapy us micardisplus treatment essential hypertension micardis plus micardisplus fixed dose combination indicat micardis hct ed adults whose blood pressure adequately hypertension comicardis telmisartan hydrochlorothiazide controlled telmisartan alone eu oiloftrop tcudorp boehringer ingelheim annual report cardiovascular etabolic diseases continued prevent vte events consequences acute myocardial infarction thopedic surgery patients receive kind thromboprophylaxis patients already suffered acute myocardial infarction heart attack occurs vte require anticoagulant treatment secondary thrombus blood clot suddenly prevents blood prevention recurrent thromboembolic event flow area heart muscle unless blood flow restored quickly affected section heart muscle becomes permanently damaged heart attacks one reversing anticoagulation common causes death industrialized coun tries anticoagulation therapy offers important benefits pa tients risk thromboembolic events however even though rare may situations rapid reversal anticoagulation medically necessary eg patient taking anticoagulant involved severe car accident needs emergency surgery hypertension cardiovascular diseases hypertension high blood pressure chronic disease blood pressure chronically elevated hyper tension also one major risk factors stroke heart attacks heart failure chronic renal failure primary goal antihypertensive treatment prevent cardiovascular events reduce risk cardio vascular mortality product portfolio human pharmaceuticals indications brand names active ingredients treatment hypertension alone antihy pertensive agents initial therapy patients likely need multiple antihypertensive agents achieve blood pressure goals us twynsta addon therapy adult patients adequately micamlo controlled blood pressure amlodipine replace micardis amlo ment therapy adult patients receiving telmisartan hypertension micardis duo telmisartan amlodipine amlodipine separate tablets eu acute ischemic stroke acute myocardial infarction acute massive pulmonary embolism fibrinolytic treatment acute ischemic stroke acute catheter clearance due actilyse myocardial infarction acute massive pulmonary thrombotic occlusion actilyse cathflo alteplase embolism fibrinolytic treatment occluded catheters secondary prevention stroke transient prevention stroke following initial first stroke ischemic attacks tia aggrenox dipyridamole acetylsalicylic acid transient ischemic attacks tia acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocardial infarction oiloftrop tcudorp boehringer ingelheim annual report cardiovascular etabolic diseases continued diabetes heart failure cardio renalmetabolic system type diabetes chronic progressive condition asso ciated elevated blood sugar levels people type diabetes high burden comorbidities risk factors include heart failure kidney disease hyper tension obesity cardiorenalmetabolic conditions affect one billion people worldwide leading cause death heart failure progressive debilitating potentially fatal condition occurs heart sup ply adequate circulation meet bodys demands oxygenated blood requires increased blood volume leading fluid accumulation congestion lungs peripheral tissues widespread condition affecting million people worldwide expected increase population ages collaborative multidisciplinary team approach op timize patient care coordinating treatment related comorbidities including use emerging medications broad cardiovascular renal metabolic effects help improve outcomes people serious chronic conditions product portfolio human pharmaceuticals indications brand names active ingredients treatment adults type diabetes mellitus adjunct diet exercise improve glycemic control reduce risk cardiovascular death adults type diabetes mellitus established cardiovascular disease jardiance us indication december label varies type diabetes mellitus jardianz empagliflozin country please refer local product information treatment adults heart failure reduced ejection fraction without type diabetes jardiance label varies country please refer local heart failure jardianz empagliflozin product information treatment adults type diabetes mellitus adjunct diet exercise improve glycemic control treatment empagliflozin synjardy metformin appropriate jardiance duo jardianz duo empagliflozin us indication december label varies type diabetes mellitus synjardy xr metformin hydrochloride country please refer local product information treatment adults type diabetes mellitus adjunct diet exercise improve glycemic control adults type diabetes mellitus empagliflozin linagliptin appropriate treatments glyxambi tradiance empagliflozin us indication march label varies country type diabetes mellitus jardianz dpp linagliptin please refer local product information trajenta treatment adults type diabetes mellitus tradjenta adjunct diet exercise improve glycemic trazenta control used mono therapy metformin tol type diabetes mellitus trayenta linagliptin erated contraindicated combination therapy jentadueto treatment adults type diabetes mellitus trayenta duo adjunct diet exercise improve glycemic trajenta duo control treatment metformin lead trajentamet sufficient control patients treated type diabetes mellitus jentadueto xr linagliptin metformin hydrochloride trajenta linagliptin metformin diabetes portfolio collaboration eli lilly company oiloftrop tcudorp boehringer ingelheim annual report oncology cancer threat global health estimated million new cases cancer diagnosed worldwide million people died cancer nearly one six global deaths world cancer factsheet common diagnosed cancer types lung cancer nearly breast cancer nearly colorectal cancer prostate cancer stomach cancer lung cancer lung cancer refers malignant abnormal cell growth side lung tissue common cancer estimated million new cases per year worldwide smoking primary cause disease contributing almost cases recently however incidence lung cancer among nonsmokers increased lung cancer poor prognosis million deaths per year representing nearly cancer deaths lung cancer symptoms unspecific disease may take many years appear late diagnosis advanced stage disease results often dismal prognosis lung cancer patients surviving five years following diagnosis different subtypes small cell lung c ancer sclc nonsmall cell lung cancer nsclc ten different molecular genetic aberrations mu tations present tumor identified focusing molecular changes specific respective subtype lung cancer targeted therapies become effective treatments show survival benefit time less harmful normal cells thereby reducing side effects product portfolio human pharmaceuticals indications brand names active ingredients firstline treatment adult patients locally advanced metastatic nonsmall cell lung cancer nsclc whose tumors activating epidermal growth factor receptor egfr mutations treatment patients locally advanced nonsmall cell lung giotrif metastatic nsclc squamous histology progressing cancer nsclc gilotrif afatinib platinumbased chemotherapy combination therapy docetaxel treatment adult patients locally advanced metastatic locally recurrent nonsmall cell lung cancer nsclc nonsmall cell lung adenocarcinoma tumor histology firstline cancer nsclc vargatef nintedanib chemotherapy oiloftrop tcudorp boehringer ingelheim annual report diseases central nervous system mental neurological diseases depression restless legs syndrome rls parkinsons disease significantly impact patients families also substantial burden society rls common neurological disorder characterized uncontrollable urge move legs primarily occur ring evening night hours usually accom parkinsons disease panied unpleasant sometimes painful sensations legs well disturbed sleep resulting daytime parkinsons disease pd degenerative disorder tiredness sleepiness sensations felt deep within central nervous system patients usually notice motor legs described creeping crawling aching symptoms like hand shaking tremor first sign disease may progress include shaking arms legs head motor symptoms may devel op time include stiffness often results loss facial expression gradual slowing loss motion freezing patients also suffer nonmotor symptoms associated pd depres sion sleep disorders primary symptoms result lack neurotransmitter dopamine dis tinct areas human brain infectious diseases hiv infection aids acquired immune deficiency syndrome aids set symptoms infections resulting damage human immune system caused human immunodefi ciency virus hiv untreated infection hiv progres sively reduces effectiveness immune system leaves individuals susceptible opportunistic infections tumors babies infected mothers risk get ting virus pregnancy childbirth breastfeeding product portfolio human pharmaceuticals indications brand names active ingredients sifrol mirapex parkinsons disease pd mirapexin symptomatic treatment idiopathic p arkinsons pexola pramipexole disease may used monotherapy com restless legs syndrome mirapex er pramipexole dihydrochloride bination levodopa symptomatic treatment rls sifrol er monohydrate idiopathic moderate severe restless legs syndrome shortterm treatment disorders initiating maintaining sleep sleep disorders lendormin brotizolam insomnia requiring pharmacological ntervention indications brand names active ingredients combination therapy hiv infection several countries prevention motherto child transmission hiv pregnant women taking antiretroviral therapy time labor viramune prolonged release tablets oncedaily dosing within hiv aids viramune xr nevirapine combination therapy indicated combination antiretroviral treatment hiv infected patients co administered mg ritonavir treatmentexperienced infected hiv strains resistant hiv aids aptivus tipranavir one protease inhibitor oiloftrop tcudorp boehringer ingelheim annual report livestock swine infectious respiratory diseases integrated health management ihm ingelvac circoflex first singledose piglet vac farmera soundtalks empower pig cine control porcine circovirus disease pcvd producers breeders retailers consumers improve ingelvac circoflex contains impranflex adjuvant health animal welfare efficiency giving insights allows fresh mixing ingelvac mycoflex predictions recommendations ihm solu form flexcombo twistpak system tions ingelvac prrs products licensed active immu nization respiratory reproductive form porcine reproductive respiratory syndrome prrs infectious enteric diseases enterisol ileitis first oral live vaccine ileitis globally prevalent enteric disease swine caused lawsonia intracellularis licensed improve weight gain reduce growth variability associated disease enterisol ileitis helps reduce total antimicrobial use pork production product portfolio animal health indications brand names active ingredients active immunization pigs age two weeks porcine circovirus type reduce mortality clinical signs including weight loss lesions lymphoid tissues associated porcine circovirus diseases pcvd addition vaccination shown reduce pcv nasal shedding viral infectious respiratory recombinant vaccine load blood lymphoid tissues duration diseases ingelvac circoflex porcine circovirus type pcv viremia ingelvac prrs mlv depending product active immuniza infectious respiratory ingelvac prrsflex eu attenuated live vaccine tion pigs various ages porcine reproduc diseases reprocyc prrs eu prrs virus type type tive respiratory syndrome virus prrs active immunization pigs age infectious respiratory inactivated vaccine three weeks reduce lung lesions following infec diseases ingelvac mycoflex mycoplasma hyopneumoniae tions mycoplasma hyopneumoniae active immunization pigs age three weeks intestinal lesions caused law sonia intracellularis infection reduce growth infectious attenuated live vaccine variability loss weight gain associated enteric disease enterisol ileitis lawsonia intracellularis disease soundtalks sound monitoring technology sound monitors gateways detects early symptoms respiratory distress respiratory diseases soundtalks algorithms swine thanks monitoring algorithms farmera allows efficient effective mobile app digital data manage proactive enabling evidencebased decision making data capture forms ment communication platform realtime information managing health tools farmera swine production production production companies soundtalks trademark soundtalks nv oiloftrop tcudorp boehringer ingelheim annual report livestock cattle ruminants cattle ruminants business global leader anti parasitic brands ivomec longrange eprinex world renowned parasiticides treat protect grazing animals harmful effects internal external parasites zactran treats cattle bacterial pneumonia sheep digital dermatitis infections bovela active immunization cattle three months age terms reproductive infectious diseases product portfolio animal health indications brand names active ingredients depending formulation product internal external treatment nematodes lice mites ticks flies lung parasites cattle ivomec ivermectin worms liver flukes theraphase technology used develop formulation eprinomectin allows single treatment last days long enough break parasite life cycle effectively reduce parasite burdens pasture longrange effective control internal external parasites internal external cattle gastrointestinal roundworms lungworms parasites cattle longrange eprinomectin longacting grubs mites depending formulation product internal external treatment nematodes lice mites ticks flies parasites ruminants eprinex eprinomectin lungworms cattle sheep depending species indication country reg istration product treatment meta bacterial causes phylaxis control respiratory disease cattle caused respiratory disease key bacteria mannheimia pasteurella histophilus interdigital dermatitis mycoplasma footrot disease sheep caused footrot zactran gamithromycin key bacteria fusobacterium dichelobacter reduces hyperthermia minimizes reduction leukocyte count caused bovine viral diarrhoea virus bvdv bvdv reduces virus shedding viremia caused bvdv prevents birth reproductive infectious bovine viral diarrhoea bvd persistently infected calves caused transplacental diseases cattle bovela types infection oiloftrop tcudorp boehringer ingelheim annual report livestock cattle ruminants continued vaccine pyramidpresponse part ex panding portfolio respiratory reproductive vaccines prevent diseases affect livestock metacam nonsteroidal antiinflammatory drug nsaid helping minimize losses inflammation tissue damage animals suffering disease hence addressing need maintained profitability concern farm animal wellbeing product portfolio animal health indications brand names active ingredients family multivalent vaccine combi nations including different modified live viruses bovine viral diarrhoea pyramidpresponse family vaccines bvd types infectious bo provides broad coverage bvd types ibr vine rhinotracheitis ibr parainflu brsv pi mannheimia haemolytica enza pi bovine respiratory single dose contain metastim adjuvant syncytial virus brsv bacteria system enhance animals response greater pasteurella multocida mannheimia protection us canada infectious respiratory haemolytica l canicola l grippoty diseases reproduc pyramid phosa l hardjo l icterohaemmor metastim registered trademark tive disorders cattle presponse rhagiae l pomona zoetis services llc treatment mastitis lactating cows control pain associated dehorning surgery also indicated use calves affected pain inflammatory diarrhoea cattle suffering respiratory disorders metacam meloxicam disease oiloftrop tcudorp boehringer ingelheim annual report livestock poultry poultry vaccine portfolio consists significant range live inactivated vectored vaccines broil ers layers breeder hens providing protection acute viral bacterial diseases like avian influ enza infectious bronchitis newcastle disease infectious bursal disease egg drop syndrome avian coryza portfolio preventive solutions helps producers world wide provide safe affordable abundant sustainable highquality poultry meat eggs product portfolio animal health indications brand names active ingredients monovalent polyvalent attenuated live inactivated vaccine contain ing antigens vaccination avian influenza newcastle disease vaccination healthy chickens diseases avian coryza egg drop syndrome caused included antigens prevention various viral gallimune infectious bronchitis infectious common diseases broiler chickens bacterial diseases gallivac bursal disease avian rhinotracheitis diseases responsible losses egg production poultry volvac salmonella gallibacterium anatis layers serotype live mareks disease infectious bursal disease vector live vhvt recombinant vaccination dayold embryos one ibd mareks disease virus contains gene ibd dayold chickens effective standard md newcastle dis vaxxitek hvt ibd virus trivalent vaccines variant infectious bursal disease mareks disease ease nd infectious vaxxitek hvt ibd nd gene ibd virus nd ilt trivalent vaccines newcastle disease laryngotracheitis ilt vaxxitek hvt ibd ilt viruses diluent infectious laryngotracheitis broiler chickens one day age active immu nization newcastle disease reduce mortality clinical signs associated disease future layer future breeder pullets age four weeks priming active immunization egg drop caused newcastle disease vacci live newcastle disease virus nation inactivated vaccine strain ulster c newcastle desease nd avinew vg gaavinew strain prior beginning lay prevexxion rn prevexxion rnhvt prevexxion rnhvtibd live herpes virus chimera vaccination dayold embryos prevexxionrn serotype strain rn onedayold chickens recommended protect mareks disease vaxxitek hvtibd diluent virulent mareks disease live mareks disease vectored virus serotype contains gene vaccination dayold embryos one newcastle mareks insert newcastle disease dayold chickens effective mareks disease diseases newxxitek hvt nd diluent newcastle disease oiloftrop tcudorp boehringer ingelheim annual report veterinary public health vph work together governments private partners toward improving control eradicating diseases footandmouth disease bluetongue virus rabies footandmouth fmd vaccines portfolio including aftopor aftovaxpur aftovax provides active immunization cattle sheep pigs reduce clinical signs mortality following exposure fmd virus rabisin inactivated vaccine rabies available clear colorless suspension injection raboral vrg oral recombinant vaccine pro tects wildlife rabies btvpur alsap multistrain vaccine used active immunization sheep cattle prevent viremia reduce clinical signs caused bluetongue virus product portfolio animal health indications brand names active ingredients aftopor aftovaxpur highly potent vaccines purified antigens recommended endemic emergency situations potential marker properties allow differentiation infected vaccinated animals diva aftovax lowcost effective vaccine profile cattle sheep suitable mass vaccination aftopor endemic situations aftovaxpur mix inactivated fmd virus footandmouth disease aftovax antigens widest range aftovaxpur doe suitable emergency situa fmd aftovaxpur doe vaccine strains tions rabisin used active immunization dogs cats reduce mortality clinical signs due rabies infection immunity demonstrated one month vaccination shown persist first booster dose year primary vaccination years following booster vaccination raboral vrg oral rabies recombinant vaccine protects wildlife raccoons foxes rabisin inactivated adjuvanted coyotes rabies thereby reducing risk rabies virus exposure rabies humans domestic animals rabisin raboral vrg vacciniavectored sold government agencies conducting rabies raboral vrg rabies vaccine rabies control programs active immunization sheep prevent viremia reduce clinical signs caused bluetongue virus serotypes combination maximum serotypes active immunization cattle prevent viremia caused bluetongue virus serotypes reduce clinical signs caused bluetongue virus serotypes combination maximum serotypes onset immunity demonstrated three weeks five weeks sheep btv primary vaccination course btv btv cattle bluetongue btvpur alsap mix inactivated bluetongue virus btv btv serotypes oiloftrop tcudorp boehringer ingelheim annual report companion animals horses equine portfolio highly comprehensive covering eqvalan duogold zimecterin gold combines key aspects equine health including parasite control ivermectin praziquantel ingredient specifically vaccination management chronic diseases controls tapeworms range flagship market leading equine prod ucts recently enhanced joint disease articell forte worlds first licensed veterinary respiratory portfolios addition new innovative stem cell product readytouse intraarticular products also line nutraceuticals injection chondrogenic induced mesenchymal cells bought without prescription treatment lameness linked noninfective joint flammation horses articell forte one prascend indicated treatment pituitary pars latest additions equine portfolio available intermedia dysfunction ppid also known range countries within eu equine cushings disease clinical signs ppid hyper trichiosis laminitis change body conformation lack aservo equihaler first inhalation product performance treatment prascend lifelong treatment severe equine asthma product novel glucocorticoid prodrug ciclesonide inhalation vetera vaccines first us vaccine portfolio solution delivered inhaler specifically designed clude multiple convenient combinations disease pro use horses implementing soft technology tection horses young four months age derived respimat inhalers human pharma vaccines protect many nine infectious exciting new introduction gained final authorization organisms including influenza herpes west nile virus product availability eu us canada tetanus others enables customized protection approvals countries expected due horse limited needle injections course gastrogardulcergard indicated treat ment prevention equine gastric ulcers one common diseases horses gastrogard supplied easytouse oral paste form first choice treatment gastric ulcers since launch ulcergard us preventive choice horses increased risk developing gastric ulcers eqvalanzimecterin contains ivermectin leading ingredient controls wide variety important inter nal parasites including bots benzimidazoleresist ant small strongyles easytoadminister oral paste eqvalanzimecterin approved adult horses foals young six weeks age product portfolio animal health indications brand names active ingredients symptomatic treatment clinical signs associated pituitary pars intermedia pituitary pars intermedia dysfunction ppid dysfunction ppid prascend pergolide mesylate also known equine cushings disease eastern western venezuelan combination vaccine encephalomyelitis tetanus west nile vaccination healthy horses aid pre nine com virus equine herpes virus equine vention diseases caused included antigens mon diseases horses vetera influenza viruses us canada treatment prevention gastric ulcers gastrogard prevention recurrence gastric ulcers horses equine gastric ulcers ulcergard omeprazole foals four weeks age older eqvalan treatment prevention parasitic infestations zimecterin horses donkeys due large small stron eqvalan gold gyles ascarids eqvalan duo ivermectin internal parasites zimecterin gold ivermectin praziquantel goldduo includes treatment tapeworms treatment mild moderate lameness linked noninfective joint inflammation horses contains reduction mild stem cells obtained equine blood moderate recurrent stem cells develop types cells lameness associated chondrogenic induced equine stem cells active substance mesenchymal stem nonseptic joint allogeneic peripheral bloodderived cells treated develop cartilage inflammation horses articell forte mesenchymal stem cells cells alleviation clinical symptoms severe equine asthma characterized coughing nasal discharge nasal flaring increased breathing effort severe equine asthma aservo equihaler ciclesonide inhalation solution rest abnormal lung sounds oiloftrop tcudorp boehringer ingelheim annual report companion animals pets pet portfolio offers diverse solutions broadline recently launched nexgard combo important needs canine feline health includ offer cat owners allinone convenience providing confi ing industryleading parasiticides vaccines pain therapy dence cat broadest possible protection therapeutics address major chronic diseases heart protect cats broadest spectrum internal failure kidney diseases hypertension epilepsy diabetes external parasites including fleas ticks heartworms mellitus osteoarthritis hookworms roundworms lungworms vesical worms tapeworms years frontline leader flea tick control dogs cats one trust boehringer ingelheim complete trusted ed brands animal health frontline continues proven range products services pain man bring innovation category recent launch agement choosing portfolio gives veterinarians frontline shield us features repellency freedom tailor treatment patient provides insecticidal efficacy many diseasecarrying flying access valueadded veterinary services insects decreases risk transmission vectorborne pathogens metacam offers extensive range formulations indications making complete nonsteoridal anti nexgard contains active ingredient afoxolaner inflammatory drug nsaid dogs cats guinea launched first oral medication pigs enables veterinarians better achieve goals treat fleas ticks dogs efficacy pain management gives owner pet exactly palatable beefflavored soft chew formulation product need ample longterm studies support nexgard currently bestselling pet medication products safety efficacy led multiple animal health industry indications across diverse species nexgard spectra combines flea tick efficacy liquid formulation metacam dogs makes afoxolaner nexgard broadspectrum de easy titrate lowest effective dose liquid worming ingredient milbemycin oxime formulation cats easy administer improved beefflavored chew nexgard spectra ef dog administration syringe aimed achieve better accu fective treating flea tick mite infestations well racy introduced gastrointestinal parasites infections also protects dogs deadly parasites heartworm lung worm heartgard plus contains active ingredients ivermectin pyrantel soft beef chew given monthly ivermectin effective preventing heartworm disease pyrantel effective treatment control roundworms well hookworms heartgard data file b abesia canis transmitted dermacentor reticulatus ticks ehrlichia launched first monthly heartworm canis transmitted rhipicephalus sanguineus ticks leishmania preventative still bestselling heartworm pre infantum transmitted phlebotmine sandflies data file ventative world data file product portfolio animal health indications brand names active ingredients frontline plusfrontline combo indicated treatment prevention flea tick lice infestations also breaks flea life cycle pre venting development flea immature stages frontline frontline triactfrontect frontline frontline combo shield indicated treatment pre frontline plus vention flea tick infestations dogs frontline triact fipronil also provide repellent activity mosquitoes antiparasitic canine frontect fipronil smethoprene sandflies ticks reducing risk transmission feline external parasites frontline shield fipronil permethrin pyriproxifen vectorborne pathogens nexgard highly palatable beefflavored chew indicated treatment prevention flea tick infestations dogs also indicated prevention borrelia burgdorferi infections antiparasitic canine us treatment demodex sarcoptes external parasites nexgard afoxolaner otodectes mite infestations nonus geographies nexgard spectra delivered highly palatable beefflavored chew indicated treatment prevention flea tick mite infestations antiparasitic canine also prevents heartworm disease angiostrongylosis internal external thelaziosis treats hookworm roundworm parasites nexgard spectra afoxolaner milbemycin oxime whipworm infestations dogs use dogs prevent canine heartworm disease eliminating tissue stage heartworm larvae antiparasitic canine month days infection treat internal parasites heartgard plus ivermectin pyrantel ment control roundworms hookworms protects cats broadest spectrum internal external parasites including adult fleas antiparasitic feline flea eggs flea larvae ticks heartworms lungworms internal external fipronil smethoprene hookworms roundworms vesical worms tape parasites broadline eprinomectin praziquantel worms spoton formulation containing esafoxolaner provide new generation flea tick control cats protects cats broadest spectrum antiparasitic feline internal external parasites including fleas ticks internal external esafoxolaner eprinomectin ear mites heartworms lungworms hookworms parasites nexgard combo praziquantel roundworms vesical worms tapeworms metacam used reduce specific types pain inflammatory postoperative pain inflammation well diseases metacam meloxicam musculoskeletal disorders dogs cats oiloftrop tcudorp boehringer ingelheim annual report companion animals pets continued previcox designed specifically dogs since launch prozinc become proven selective veterinary cox inhibitor previcox insulin choice feline patients owners con provides safe sustained pain relief fast onset ac venient management feline diabetes approval tion longterm safety efficacy established prozinc canine patients opportunity large field studies previcox shown become firstchoice solution successful man efficacious competition acute models agement diabetes dogs cats large clinical osteoarthritis studies europe us japan confirmed majority dogs managed one injection vetmedin inodilator become stan prozinc insulin per day major breakthrough dard care treating dogs congestive heart dogs owners veterinarians failure caused dilated cardiomyopathy valvular sufficiency mitral tricuspid regurgitation pet vaccine product portfolio includes purevax used combination furosemide significantly im feline vaccines formulated provide effective protection proves clinical signs extends life expectancy without use adjuvants catfriendly patients recent studies also shown used vaccination purevax launched reduced preclinical asymptomatic cases either dilated cardio ml volume us france myopathy doberman pinschers valvular insufficiency recombitek offers complete line advanced canine vetmedin significantly delays onset clinical signs vaccines providing targeted protection recombi congestive heart failure first veterinary cardiology nant technology rabisin imrab provide trusted vaccines fight rabies decades proven semintra firstever licensed angiotensin receptor efficacy safety blocker veterinary use specifically designed cats semintra scientifically advanced treatment one simple solution safely effectively harnesses protective benefits cats reninangiotensin aldosterone system protect kidneys key organs semintra available mgml mgml oral solution semintra mgml first launched reduction proteinuria associated chronic kidney disease cats semintra mgml launched control us treatment eu feline systemic hypertension first vetlicensed product feline hypertension us product portfolio animal health indications brand names active ingredients relief pain inflammation associated pain inflammatory osteoarthritis well specific types diseases previcox firocoxib postoperative pain dogs treatment canine congestive heart failure originat ing dilated cardiomyopathy valvular insuffi ciency mitral tricuspid regurgitation treatment dilated cardiomyopathy preclinical stage asymptomatic increase left ventricu lar endsystolic enddiastolic diameter doberman pinschers treatment dogs myxomatous mitral valve disease mmvd preclinical stage asympto matic systolic mitral murmur evidence increased heart size delay onset clinical congestive heart failure vetmedin pimobendan symptoms heart failure chronic kidney disease ckd cats management chronic kidney disease ckd hypertension cats semintra telmisartan feline systemic hypertension us eu cats treatment diabetes mellitus cats dogs achieve reduction hyperglycemia improve diabetes prozinc protamine zinc ment associated clinical signs feline herpes virus feline calicivirus feline panleukopenia virus chlamydia purevax fully adjuvantfree feline felis recombinant vectored feline vaccine range leverages innovative canarypox leukemia virus recombinant vectored technology felv rabies also offers sustained feline vaccines portfolio purevax rabies virus protection rabies three years recombinant vectored caninedistem per virus canine parvovirus canine recombitek features complete line canine adenovirus type canine parain vaccines including fluenza virus canine coronavirus leptospira canicola leptospira recombitek lyme vaccine contains grippotyphosa leptospira ictero ospa nonadjuvant formulation haemorrhagiae leptospira pomona canine vaccines recombinant borrelia burgdorferi recombitek oral bordatella effective safe portfolio rekombitek bordetella bronchiseptica protection made easy sustained rabies protection three years rabies vaccines rabisin inactivated adjuvanted first year booster consistently high seroconversion portfolio imrab rabies glycoproteins rate rabies protection six species us others oiloftrop tcudorpch boehringer sohn ag co kg ingelheim rhein comparison balance sheet financial data assets december million eur intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets incl prepaid expenses deferred taxes exceeding amount plan assets financial funds current assets total assets equity liabilities december million eur shareholders capital group reserves incl balance sheet currency conversion difference group profit equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions incl deferred taxes liabilities incl deferred income total liabilities incl deferred taxes deferred income total equity liabilities summary selected financial data million eur net sales operating income operating income net sales income taxes income taxes net sales equity ratio cash flow operating activities financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd net sales investments tangible assets depreciation tangible assets imprint assets december ch boehringer sohn ag co kg million eur binger strasse intangible assets ingelheim rhein tangible assets germany financial assets telephone fax fixed assets inventories contact accounts receivable assets incl prepaid expenses corporate affairs deferred taxes exceeding amount plan assets matthias reinig financial funds pressboehringeringelheimcom current assets boehringeringelheimcom total assets issued equity liabilities december ch boehringer sohn ag co kg represented board managing directors million eur hubertus von baumbach chair shareholders capital carinne brouillon dr michel pairet group reserves incl balance sheet currency conversion difference jean scheftsik de szolnok michael schmelmer group profit concept design layout equity attributable parent company st kommunikation gmbh mainz noncontrolling interests wwwstde group equity difference capital consolidation photos provisions incl deferred taxes andreas reeg pages lennart nilsson pages getty images liabilities incl deferred income total liabilities incl deferred taxes deferred income printed total equity liabilities eberl koesel gmbh co kg altusriedkrugzell summary selected financial data copyright ch boehringer sohn ag co kg million eur rights reserved part annual report may reproduced trans net sales mitted form means electronic photocopy without permission operating income writing ch boehringer sohn ag co kg figures third parties used operating income net sales annual report based data available time financial statements drawn income taxes income taxes net sales equity ratio cash flow operating activities financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd net sales investments tangible assets co emission certificates support forest conservation depreciation tangible assets forest modification many regions germanyboehringeringelheimcom annualreportboehringeringelheimcom troper launna miehlegni regnirheob